,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,ABI3,"NESH, SSH3BP3",ENSG00000108798,ABI family member 3,17,49210227-49223225,Predicted intracellular proteins,Evidence at protein level,HPA017345,Enhanced,,,,Endometrial cancer:7.13e-4 (favourable),Expressed in all,Tissue enhanced,,spleen: 62.0,lymph node: 29.9,Cell line enhanced,,Daudi: 28.2;HDLM-2: 21.3;HUVEC TERT2: 54.6;TIME: 38.1
1,ABLIM2,KIAA1808,ENSG00000163995,Actin binding LIM protein family member 2,4,7965310-8158832,Predicted intracellular proteins,Evidence at protein level,HPA035808,Uncertain,,Approved,Nucleoplasm<br>Mitochondria,,Mixed,Tissue enhanced,,skeletal muscle: 37.5;spleen: 28.4,cerebral cortex: 22.1,Group enriched,6.0,SCLC-21H: 16.3;SiHa: 6.6;U-2197: 19.7
2,AC009133.22,,ENSG00000277669,,16,29663279-29695144,Predicted secreted proteins,Evidence at protein level,HPA011887,Uncertain,,,,,Not detected,Tissue enhanced,,colon: 2.6;duodenum: 1.8;spleen: 1.0,lung: 0.4,Cell line enhanced,,BEWO: 44.0;EFO-21: 114.1;SH-SY5Y: 19.3
3,AC037459.4,,ENSG00000248235,,8,22589274-22602084,Predicted intracellular proteins,Evidence at transcript level,HPA024667,Uncertain,,,,,Not detected,Tissue enhanced,,spleen: 3.6,small intestine: 1.9,Cell line enhanced,,U-2197: 3.5
4,AC069368.3,,ENSG00000249240,,15,64841883-64930920,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,spleen: 8.8,appendix: 6.1,Cell line enhanced,,U-266/84: 21.3
5,ADAM8,"CD156, CD156a, MS2",ENSG00000151651,ADAM metallopeptidase domain 8,10,133262403-133276868,"CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA064637,Approved,,,,Renal cancer:3.99e-10 (unfavourable),Expressed in all,Tissue enhanced,,bone marrow: 43.8;spleen: 32.9,appendix: 30.1,Cell line enhanced,,A-431: 51.7;BEWO: 78.4;CAPAN-2: 61.7;HaCaT: 61.1;HDLM-2: 42.3;U-87 MG: 33.6
6,ADGRE1,"EMR1, TM7LN3",ENSG00000174837,Adhesion G protein-coupled receptor E1,19,6887566-6940459,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at transcript level,HPA052809,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 9.9;spleen: 19.7,lung: 6.8,Cell line enhanced,,BJ hTERT+: 8.5;HDLM-2: 24.5;HMC-1: 15.9;Karpas-707: 16.0
7,ADGRE2,"CD312, EMR2",ENSG00000127507,Adhesion G protein-coupled receptor E2,19,14732393-14778541,"CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA055200,,,Uncertain,Vesicles,Renal cancer:4.35e-6 (unfavourable),Mixed,Tissue enhanced,,appendix: 27.0;spleen: 15.4,adipose tissue: 6.0,Cell line enhanced,,HEL: 10.6;HMC-1: 16.0;U-937: 11.8
8,ADGRE3,EMR3,ENSG00000131355,Adhesion G protein-coupled receptor E3,19,14619117-14690027,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA015638,Uncertain,,,,,Not detected,Tissue enhanced,,appendix: 8.7;spleen: 8.6,lung: 3.9,Cell line enriched,50.0,HMC-1: 39.7
9,ADRA1B,,ENSG00000170214,Adrenoceptor alpha 1B,5,159916783-159972544,"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA074416,,,Supported,Plasma membrane,"Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 14.8;spleen: 17.0,ovary: 4.8,Cell line enhanced,,EFO-21: 12.8;TIME: 10.9;U-2 OS: 9.6
10,AIF1,"AIF-1, Em:AF129756.17, IBA1, IRT-1",ENSG00000204472,Allograft inflammatory factor 1,6,31615184-31617021,Predicted intracellular proteins,Evidence at protein level,"HPA049234, HPA062949",Enhanced,,Approved,Cytosol,Renal cancer:2.30e-5 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 78.3,appendix: 50.3,Cell line enhanced,,HEL: 79.8;HMC-1: 107.9;NB-4: 129.5;THP-1: 46.4
11,AIF1L,"C9orf58, FLJ12783, IBA2",ENSG00000126878,Allograft inflammatory factor 1 like,9,131096476-131123152,Predicted intracellular proteins,Evidence at protein level,"HPA020522, HPA056852",Enhanced,,,,Renal cancer:5.54e-6 (favourable),Expressed in all,Tissue enhanced,,kidney: 287.5;spleen: 288.1,thyroid gland: 155.2,Cell line enhanced,,AF22: 139.6;NTERA-2: 106.7;RPTEC TERT1: 230.5
12,AIM2,PYHIN4,ENSG00000163568,Absent in melanoma 2,1,159062484-159147096,Predicted intracellular proteins,Evidence at protein level,"HPA031365, HPA040309",Uncertain,,Supported,Nucleoplasm<br>Mitochondria<br>Cytosol,,Mixed,Tissue enhanced,,lymph node: 52.5;spleen: 30.9;tonsil: 40.1,appendix: 26.0,Cell line enhanced,,Daudi: 60.6;HDLM-2: 110.5;Karpas-707: 32.8;U-266/70: 28.9;U-87 MG: 34.1
13,ALG1L2,,ENSG00000251287,"ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase like 2",3,130081831-130113227,Predicted intracellular proteins,Evidence at protein level,HPA060392,Uncertain,,Uncertain,Nucleoli fibrillar center<br>Endoplasmic reticulum,Ovarian cancer:7.75e-4 (favourable),Mixed,Tissue enhanced,,spleen: 1.0,"appendix,duodenum,skin: 0.2",Not detected,,
14,AOAH,,ENSG00000136250,Acyloxyacyl hydrolase,7,36512949-36724549,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA021666, HPA026716",Uncertain,,,,,Expressed in all,Tissue enhanced,,spleen: 88.9,appendix: 45.9,Group enriched,6.0,HDLM-2: 3.4;NB-4: 16.7;THP-1: 13.5;U-937: 6.8
15,APOBR,"APOB100R, APOB48R",ENSG00000184730,Apolipoprotein B receptor,16,28494649-28498970,Predicted intracellular proteins,Evidence at protein level,"HPA041667, HPA042093",Enhanced,,,,Endometrial cancer:3.26e-4 (favourable),Expressed in all,Tissue enhanced,,spleen: 30.4,appendix: 27.1,Cell line enhanced,,HEL: 37.0;HMC-1: 109.0;NB-4: 22.6;U-937: 24.2
16,ARHGAP25,KIAA0053,ENSG00000163219,Rho GTPase activating protein 25,2,68679601-68826833,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035346, HPA061395",Enhanced,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.93e-4 (unfavourable), Cervical cancer:7.72e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 89.6,lymph node: 81.2,Cell line enhanced,,HEL: 59.7;HMC-1: 225.1
17,ARHGAP30,FLJ00267,ENSG00000186517,Rho GTPase activating protein 30,1,161046946-161069970,Predicted intracellular proteins,Evidence at protein level,HPA036300,Uncertain,,Supported,Vesicles,Renal cancer:9.78e-4 (unfavourable),Expressed in all,Tissue enhanced,,lymph node: 86.1;spleen: 80.6,appendix: 73.2,Cell line enhanced,,Daudi: 82.8;HL-60: 72.0;HMC-1: 106.5;U-266/70: 103.3
18,ARHGAP4,"C1, KIAA0131, p115, RhoGAP4, SrGAP4",ENSG00000089820,Rho GTPase activating protein 4,X,153907367-153934999,Predicted intracellular proteins,Evidence at protein level,"HPA001012, HPA001083",Enhanced,,Approved,Nucleoplasm<br>Focal adhesion sites,"Colorectal cancer:1.97e-5 (unfavourable), Cervical cancer:3.94e-5 (favourable), Renal cancer:2.49e-4 (unfavourable), Head and neck cancer:3.31e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 95.1,lymph node: 87.2,Cell line enhanced,,MOLT-4: 72.4;RPMI-8226: 121.4
19,ARHGAP45,"HA-1, HMHA1, KIAA0223",ENSG00000180448,Rho GTPase activating protein 45,19,1065923-1086628,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA019816,Enhanced,,,,"Endometrial cancer:6.02e-4 (favourable), Head and neck cancer:7.82e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 56.4;lymph node: 66.6;spleen: 77.8,bone marrow: 44.0,Cell line enhanced,,Karpas-707: 72.0;U-266/70: 99.7
20,ART4,"CD297, DO, DOK1",ENSG00000111339,ADP-ribosyltransferase 4 (Dombrock blood group),12,14825569-14843495,"Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA075664,,,Approved,Rods & Rings,,Tissue enhanced,Tissue enhanced,,liver: 27.2;spleen: 26.9,gallbladder: 15.1,Cell line enhanced,,AN3-CA: 5.6;HEL: 10.9;Hep G2: 4.9;HUVEC TERT2: 22.5
21,C10orf105,FLJ00245,ENSG00000214688,Chromosome 10 open reading frame 105,10,71711702-71737824,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 2.3;spleen: 3.2,testis: 1.4,Cell line enriched,6.0,BJ hTERT+: 2.6
22,C11orf21,,ENSG00000110665,Chromosome 11 open reading frame 21,11,2295645-2303049,Predicted intracellular proteins,Evidence at transcript level,HPA037607,Approved,,,,,Mixed,Tissue enhanced,,bone marrow: 32.4;spleen: 17.6,lymph node: 15.9,Cell line enhanced,,HEL: 45.5;HL-60: 15.4;NB-4: 11.2;U-937: 16.8
23,C5AR2,"C5L2, GPR77",ENSG00000134830,Complement component 5a receptor 2,19,47332147-47347327,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA016629,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,spleen: 9.7,appendix: 5.9,Group enriched,6.0,MCF7: 15.8;T-47d: 23.3
24,CABP4,CSNB2B,ENSG00000175544,Calcium binding protein 4,11,67452406-67460313,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,spleen: 10.0,"epididymis,placenta: 2.4",Cell line enhanced,,CAPAN-2: 4.4;HMC-1: 18.9
25,CARD11,"BIMP3, CARMA1",ENSG00000198286,Caspase recruitment domain family member 11,7,2906141-3043945,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA052984,Approved,,,,"Renal cancer:6.68e-8 (unfavourable), Urothelial cancer:1.10e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 54.4;spleen: 40.2,appendix: 28.3,Cell line enhanced,,Daudi: 86.5;RT4: 71.8;U-698: 73.9
26,CARD9,,ENSG00000187796,Caspase recruitment domain family member 9,9,136361903-136373681,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA059502,Enhanced,,,,,Mixed,Tissue enhanced,,bone marrow: 7.1;spleen: 8.2,appendix: 5.7,Cell line enhanced,,HMC-1: 49.3;NB-4: 30.7;THP-1: 30.1
27,CARMIL2,"LRRC16C, RLTPR",ENSG00000159753,Capping protein regulator and myosin 1 linker 2,16,67644919-67657569,Predicted intracellular proteins,Evidence at protein level,HPA041402,Approved,,,,,Mixed,Tissue enhanced,,appendix: 16.2;lymph node: 25.0;spleen: 15.1,tonsil: 10.1,Cell line enhanced,,Daudi: 45.8;MOLT-4: 51.3;REH: 96.9;RPMI-8226: 40.2;U-698: 73.2
28,CBFA2T3,"ETO2, MTG16, MTGR2, RUNX1T3, ZMYND4",ENSG00000129993,CBFA2/RUNX1 translocation partner 3,16,88874858-88977204,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA059931, HPA062423, HPA065890",Approved,,Enhanced,Nucleoplasm,Head and neck cancer:3.95e-4 (favourable),Mixed,Tissue enhanced,,spleen: 18.7,lymph node: 10.4,Cell line enhanced,,HEL: 57.7;K-562: 102.3;MOLT-4: 46.5;REH: 103.4;T-47d: 47.0
29,CCDC88B,"BRLZ, CCDC88, FLJ00354, FLJ37970, GIPIE, HkRP3",ENSG00000168071,Coiled-coil domain containing 88B,11,64340223-64357534,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA026652,Approved,,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,"Renal cancer:7.65e-5 (unfavourable), Head and neck cancer:1.48e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 36.2,bone marrow: 31.3,Cell line enhanced,,HMC-1: 73.4;THP-1: 23.2
30,CCL14,"CKb1, HCC-1, HCC-3, MCIF, NCC-2, SCYA14, SCYL2",ENSG00000276409,C-C motif chemokine ligand 14,17,35983291-35987004,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB004423, HPA030268",Uncertain,,,,,Mixed,Tissue enhanced,,spleen: 271.8,adipose tissue: 123.7,Cell line enriched,53.0,HUVEC TERT2: 46.6
31,CCL4,"Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4",ENSG00000275302,C-C motif chemokine ligand 4,17,36103590-36105621,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,CAB007805,Approved,,,,"Endometrial cancer:1.97e-5 (favourable), Renal cancer:1.68e-4 (unfavourable), Colorectal cancer:3.54e-4 (favourable), Melanoma:3.97e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 24.8,lymph node: 17.6,Group enriched,22.0,Karpas-707: 2.2;U-266/70: 5.1;U-266/84: 2.4
32,CCL5,"D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228",ENSG00000271503,C-C motif chemokine ligand 5,17,35871491-35880793,"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:3.61e-7 (unfavourable), Endometrial cancer:1.34e-5 (favourable), Melanoma:2.42e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 80.5,lymph node: 68.5,Group enriched,7.0,HL-60: 31.8;NB-4: 158.3;THP-1: 39.1;U-937: 41.8
33,CD160,"BY55, NK1, NK28",ENSG00000117281,CD160 molecule,1,145719471-145739288,"CD markers, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,spleen: 19.6,small intestine: 5.1,Mixed,,
34,CD163L1,"CD163B, M160, SCARI2",ENSG00000177675,CD163 molecule like 1,12,7346685-7479897,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA015663,Enhanced,,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,,Mixed,Tissue enhanced,,spleen: 43.2,rectum: 24.1,Cell line enhanced,,U-87 MG: 22.1
35,CD1C,CD1,ENSG00000158481,CD1c molecule,1,158289786-158293630,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Cervical cancer:1.79e-5 (favourable),Mixed,Tissue enhanced,,spleen: 40.6;tonsil: 45.1,lymph node: 39.8,Cell line enriched,16.0,MOLT-4: 46.0
36,CD200R1,"CD200R, HCRTR2, MOX2R, OX2R",ENSG00000163606,CD200 receptor 1,3,112921209-112975122,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA068512,,,Supported,Plasma membrane,,Mixed,Tissue enhanced,,spleen: 14.5,placenta: 10.2,Cell line enriched,8.0,HEL: 26.4
37,CD22,"SIGLEC-2, SIGLEC2",ENSG00000012124,CD22 molecule,19,35319261-35347355,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002418, HPA024353",Enhanced,,,,,Mixed,Tissue enhanced,,lymph node: 264.4;ovary: 162.2;spleen: 151.7;tonsil: 210.1,appendix: 98.1,Group enriched,11.0,Daudi: 201.6;REH: 76.6;U-698: 153.7;WM-115: 49.6
38,CD244,"2B4, NAIL, NKR2B4, Nmrk, SLAMF4",ENSG00000122223,CD244 molecule,1,160830160-160862855,"CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,spleen: 23.5,bone marrow: 6.2,Cell line enhanced,,HEL: 18.7;HMC-1: 61.7;U-937: 22.7
39,CD247,"CD3H, CD3Q, CD3Z",ENSG00000198821,CD247 molecule,1,167430640-167518610,"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB004651, HPA008750",Enhanced,,,,"Endometrial cancer:8.63e-6 (favourable), Renal cancer:9.94e-6 (unfavourable), Head and neck cancer:3.98e-4 (favourable), Breast cancer:9.12e-4 (favourable)",Mixed,Tissue enhanced,,lymph node: 65.1;spleen: 48.6,tonsil: 33.6,Group enriched,34.0,HDLM-2: 144.2;MOLT-4: 133.0
40,CD300A,"CMRF-35-H9, CMRF35H, IGSF12, IRC1, IRC2, Irp60",ENSG00000167851,CD300a molecule,17,74466416-74484796,"CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA011645,Approved,,,,Renal cancer:1.91e-5 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 85.8,appendix: 40.0,Cell line enhanced,,HMC-1: 88.9;NB-4: 27.4;RPMI-8226: 57.9
41,CD300LF,"CD300f, CLM1, IGSF13, IREM1, NKIR",ENSG00000186074,CD300 molecule like family member f,17,74694311-74712978,"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA013712,Supported,,,,,Expressed in all,Tissue enhanced,,lung: 25.6;spleen: 28.0,appendix: 18.2,Group enriched,7.0,THP-1: 16.6;U-937: 37.2
42,CD33,"FLJ00391, p67, SIGLEC-3, SIGLEC3",ENSG00000105383,CD33 molecule,19,51225064-51243860,"CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB011442, HPA035832, HPA064807",Approved,,Supported,Nucleus<br>Plasma membrane,,Mixed,Tissue enhanced,,spleen: 33.1,bone marrow: 20.9,Cell line enhanced,,HEL: 77.8;HL-60: 92.6;HMC-1: 72.6;RPMI-8226: 43.3;THP-1: 45.3;U-937: 66.2
43,CD37,TSPAN26,ENSG00000104894,CD37 molecule,19,49335171-49343335,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002492, HPA032120, HPA032121",Enhanced,,,,Endometrial cancer:4.51e-4 (favourable),Expressed in all,Tissue enhanced,,lymph node: 241.4;spleen: 208.7,appendix: 129.0,Cell line enhanced,,Daudi: 215.5;HMC-1: 252.2;RPMI-8226: 75.0;THP-1: 72.1
44,CD48,"BCM1, BLAST, hCD48, mCD48, SLAMF2",ENSG00000117091,CD48 molecule,1,160678746-160711851,"CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002497, HPA055146",Enhanced,,Supported,Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 311.4;spleen: 213.1;tonsil: 226.0,appendix: 148.5,Cell line enhanced,,Daudi: 153.4;HMC-1: 202.6;U-266/70: 372.1;U-266/84: 244.7
45,CD7,"GP40, LEU-9, Tp40, TP41",ENSG00000173762,CD7 molecule,17,82314868-82317602,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002594, HPA039079",Enhanced,,,,"Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 43.1;lymph node: 41.5;spleen: 43.1,small intestine: 17.0,Group enriched,5.0,Hep G2: 35.2;MOLT-4: 95.7
46,CD8A,CD8,ENSG00000153563,CD8a molecule,2,86784610-86808396,"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000012, HPA037756, CAB075722",Enhanced,,,,"Endometrial cancer:6.15e-6 (favourable), Renal cancer:1.91e-5 (unfavourable), Cervical cancer:4.54e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 161.9,lymph node: 46.9,Cell line enriched,5.0,MOLT-4: 11.7
47,CDH4,,ENSG00000179242,Cadherin 4,20,61252426-61940617,Predicted membrane proteins,Evidence at protein level,HPA015613,,,Enhanced,Plasma membrane,,Group enriched,Tissue enhanced,,cerebral cortex: 6.0;spleen: 4.8,seminal vesicle: 1.3,Cell line enhanced,,AF22: 11.0;hTERT-HME1: 11.2;U-2 OS: 20.6;U-251 MG: 29.8
48,CFP,PFC,ENSG00000126759,Complement factor properdin,X,47623172-47630305,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,bone marrow: 58.1;spleen: 76.6,appendix: 29.9,Cell line enhanced,,EFO-21: 21.2;HEL: 4.6;HMC-1: 4.9;NB-4: 7.2;U-937: 6.1
49,CHODL,"C21orf68, FLJ12627, MT75, PRED12",ENSG00000154645,Chondrolectin,21,17901263-18267373,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017282,Enhanced,Supported,,,Endometrial cancer:1.18e-6 (unfavourable),Mixed,Tissue enhanced,,spleen: 19.5;testis: 57.6,prostate: 9.3,Cell line enhanced,,U-266/70: 2.1;U-266/84: 5.1;U-87 MG: 7.6
50,CHRM4,,ENSG00000180720,Cholinergic receptor muscarinic 4,11,46385098-46386608,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022444, HPA072083",Uncertain,,Uncertain,Nucleus<br>Golgi apparatus,,Mixed,Tissue enhanced,,cerebral cortex: 8.1;small intestine: 7.8;spleen: 21.4,testis: 6.9,Cell line enhanced,,RH-30: 3.3;SCLC-21H: 11.7;U-2 OS: 3.0
51,CLEC3B,"TN, TNA",ENSG00000163815,C-type lectin domain family 3 member B,3,45001548-45036071,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB002582, HPA034794",Approved,,,,"Liver cancer:9.99e-9 (favourable), Head and neck cancer:1.53e-4 (favourable), Pancreatic cancer:5.68e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 303.3,adipose tissue: 203.9,Cell line enhanced,,ASC diff: 169.4;ASC TERT1: 341.9;U-2197: 94.5
52,CLEC4C,"BDCA2, CD303, CLECSF11, CLECSF7, DLEC, HECL",ENSG00000198178,C-type lectin domain family 4 member C,12,7729415-7751605,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029432,Approved,,,,,Not detected,Tissue enhanced,,lymph node: 6.0;spleen: 4.6;tonsil: 4.5,"appendix,breast: 1.8",Cell line enhanced,,HDLM-2: 1.9
53,CLEC4E,"CLECSF9, mincle",ENSG00000166523,C-type lectin domain family 4 member E,12,8533305-8540963,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA004935,Uncertain,,Uncertain,Cytosol,,Mixed,Tissue enhanced,,appendix: 53.9;bone marrow: 49.6;spleen: 44.0,gallbladder: 18.9,Cell line enhanced,,NB-4: 2.8;RPTEC TERT1: 9.2
54,CLEC9A,"CD370, DNGR-1, HEEE9341, UNQ9341",ENSG00000197992,C-type lectin domain family 9 member A,12,10030677-10066027,Predicted membrane proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,lymph node: 7.8;spleen: 6.6,testis: 5.5,Not detected,,
55,CLECL1,DCAL1,ENSG00000184293,C-type lectin like 1,12,9715860-9733299,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,lymph node: 28.7;spleen: 22.6;tonsil: 28.3,appendix: 13.3,Group enriched,5.0,HEL: 44.5;Karpas-707: 47.7;U-698: 120.2;U-937: 75.2
56,CR1,"CD35, KN",ENSG00000203710,Complement C3b/C4b receptor 1 (Knops blood group),1,207496147-207640647,"Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB002491, CAB016271, HPA042455, HPA043579, HPA049348",Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 37.5;spleen: 33.6,lymph node: 23.4,Group enriched,8.0,HL-60: 7.8;HMC-1: 19.1;NB-4: 5.8
57,CRHBP,"CRF-BP, CRFBP",ENSG00000145708,Corticotropin releasing hormone binding protein,5,76952713-76981158,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA046120,Approved,,,,,Tissue enhanced,Tissue enhanced,,liver: 69.9;spleen: 42.2,kidney: 30.2,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 3.2;BJ hTERT+ SV40 Large T+ RasG12V: 3.3;HBF TERT88: 6.0;U-698: 4.8;U-87 MG: 3.6;WM-115: 3.2
58,CTB-133G6.1,,ENSG00000263264,,19,7348943-7383385,Predicted membrane proteins,Evidence at protein level,HPA049151,Uncertain,,,,,Mixed,Tissue enhanced,,lymph node: 22.3;spleen: 16.5,appendix: 15.3,Cell line enhanced,,Daudi: 38.3;HL-60: 18.6;MOLT-4: 18.2;REH: 18.9;THP-1: 15.0;U-698: 23.8;U-937: 14.2
59,CTD-2545M3.6,,ENSG00000142539,,19,50415799-50428409,Predicted intracellular proteins,Evidence at transcript level,HPA018523,Uncertain,,,,,Not detected,Tissue enhanced,,appendix: 1.3;spleen: 1.8,"duodenum,lymph node: 0.6",Cell line enhanced,,REH: 2.7;U-2 OS: 1.1;U-266/70: 1.2;U-698: 1.3
60,CTSW,,ENSG00000172543,Cathepsin W,11,65879809-65883741,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,CAB016345,Enhanced,,,,"Endometrial cancer:8.36e-6 (favourable), Renal cancer:8.84e-6 (unfavourable), Breast cancer:3.06e-4 (favourable), Head and neck cancer:9.89e-4 (favourable)",Expressed in all,Tissue enhanced,,bone marrow: 70.6;spleen: 60.4,lung: 36.5,Group enriched,20.0,HEL: 149.5;NB-4: 242.5
61,CXCL1,"FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1",ENSG00000163739,C-X-C motif chemokine ligand 1,4,73869393-73871242,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:1.60e-4 (unfavourable), Liver cancer:2.91e-4 (unfavourable), Cervical cancer:7.23e-4 (unfavourable), Breast cancer:7.83e-4 (favourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 178.6;spleen: 112.8",urinary bladder: 92.0,Group enriched,7.0,BJ hTERT+: 658.8;EFO-21: 1914.4;RPTEC TERT1: 559.0
62,CXCL6,"CKA-3, GCP-2, SCYB6",ENSG00000124875,C-X-C motif chemokine ligand 6,4,73836497-73849064,Predicted secreted proteins,Evidence at protein level,,,,,,Renal cancer:4.82e-4 (unfavourable),Mixed,Tissue enhanced,,gallbladder: 50.3;spleen: 112.9,urinary bladder: 32.4,Group enriched,6.0,BJ hTERT+: 36.7;EFO-21: 100.3;hTEC/SVTERT24-B: 22.6;HUVEC TERT2: 59.0;RPTEC TERT1: 62.9
63,CXCR1,"CD181, CDw128a, CKR-1, CMKAR1, IL8RA",ENSG00000163464,C-X-C motif chemokine receptor 1,2,218162845-218166995,"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA031991,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 35.1;spleen: 25.0,adipose tissue: 15.7,Cell line enriched,32.0,HMC-1: 5.0
64,CXCR2,"CD182, CMKAR2, IL8RB",ENSG00000180871,C-X-C motif chemokine receptor 2,2,218125289-218137253,"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB016268, HPA031999, HPA032017",Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 55.7;spleen: 36.7,esophagus: 29.9,Group enriched,10.0,BEWO: 13.6;HL-60: 6.5;HMC-1: 14.3;THP-1: 10.4;U-937: 11.8
65,CXCR5,"BLR1, CD185, MDR15",ENSG00000160683,C-X-C motif chemokine receptor 5,11,118883766-118897799,"CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB026149, HPA042432",Enhanced,,,,,Not detected,Tissue enhanced,,appendix: 14.5;lymph node: 32.5;spleen: 21.0;tonsil: 14.3,bone marrow: 6.4,Group enriched,8.0,Daudi: 12.9;U-698: 43.3
66,DENND1C,"FAM31C, FLJ22757",ENSG00000205744,DENN domain containing 1C,19,6467207-6482557,Predicted intracellular proteins,Evidence at protein level,"HPA042758, HPA042839",Enhanced,,,,"Renal cancer:7.51e-14 (favourable), Lung cancer:1.23e-4 (favourable), Urothelial cancer:5.62e-4 (favourable), Prostate cancer:8.95e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 28.2;lymph node: 37.1;spleen: 31.7,bone marrow: 14.0,Cell line enhanced,,Daudi: 16.1;HEL: 13.5;HMC-1: 39.4;U-937: 24.3
67,DNASE1L3,"DNAS1L3, LSD",ENSG00000163687,Deoxyribonuclease 1 like 3,3,58192257-58214697,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA019955,Approved,,,,"Renal cancer:1.06e-7 (favourable), Liver cancer:1.20e-6 (favourable)",Mixed,Tissue enhanced,,liver: 136.7;spleen: 316.5,tonsil: 51.2,Cell line enhanced,,BEWO: 1.8;RPMI-8226: 1.4
68,DPEP2,,ENSG00000167261,Dipeptidase 2,16,67987394-68000586,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035644,Approved,,,,Testis cancer:8.47e-4 (unfavourable),Mixed,Tissue enhanced,,spleen: 38.7,lung: 27.9,Cell line enhanced,,HEL: 3.7;HMC-1: 16.1;U-937: 4.9
69,EOMES,TBR2,ENSG00000163508,Eomesodermin,3,27715949-27722711,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA028896,Uncertain,,,,Renal cancer:9.45e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,lymph node: 18.2;spleen: 19.4,tonsil: 5.3,Cell line enhanced,,HDLM-2: 7.3;SCLC-21H: 4.9
70,EPHA8,"EEK, Hek3",ENSG00000070886,EPH receptor A8,1,22563564-22603594,"Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB009660, HPA031433",Uncertain,,,,,Mixed,Tissue enhanced,,adrenal gland: 4.7;spleen: 2.6;testis: 1.9,cerebral cortex: 1.3,Cell line enriched,14.0,SCLC-21H: 70.4
71,EVI2B,"CD361, D17S376, EVDB",ENSG00000185862,Ecotropic viral integration site 2B,17,31303766-31314112,"CD markers, Predicted membrane proteins",Evidence at protein level,HPA007436,Enhanced,,,,Renal cancer:2.05e-4 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 213.7,lymph node: 175.0,Cell line enhanced,,HL-60: 77.7;HMC-1: 114.9;Karpas-707: 67.2;RPMI-8226: 98.3;THP-1: 81.9
72,EXOC3L1,"EXOC3L, FLJ35539, FLJ35587",ENSG00000179044,Exocyst complex component 3 like 1,16,67184366-67190204,Predicted intracellular proteins,Evidence at transcript level,HPA029574,Uncertain,,Approved,Vesicles<br>Plasma membrane,,Expressed in all,Tissue enhanced,,spleen: 30.0,placenta: 8.4,Cell line enhanced,,HUVEC TERT2: 2.8;SCLC-21H: 7.6
73,FAM110B,"C8orf72, MGC39325",ENSG00000169122,Family with sequence similarity 110 member B,8,57994509-58204279,Predicted intracellular proteins,Evidence at protein level,"HPA008318, HPA011781",Uncertain,,Supported,Mitochondria<br>Cytosol,"Endometrial cancer:3.88e-8 (unfavourable), Renal cancer:4.31e-8 (favourable), Pancreatic cancer:1.44e-4 (favourable)",Mixed,Tissue enhanced,,spleen: 28.2,cerebral cortex: 17.7,Cell line enhanced,,RPTEC TERT1: 9.6
74,FAM26F,"C6orf187, dJ93H18.5, INAM, OTTHUMP00000017061, OTTHUMP00000017062, RP1-93H18.5",ENSG00000188820,Family with sequence similarity 26 member F,6,116461370-116463779,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,Renal cancer:9.31e-10 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 170.6,appendix: 80.5,Cell line enhanced,,Karpas-707: 33.4;RPMI-8226: 110.4;U-937: 46.8
75,FAM43A,FLJ90022,ENSG00000185112,Family with sequence similarity 43 member A,3,194686544-194689037,Predicted intracellular proteins,Evidence at protein level,HPA048345,Uncertain,,Approved,Vesicles,Urothelial cancer:9.96e-4 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 34.0,placenta: 18.2,Cell line enhanced,,HUVEC TERT2: 113.2;NB-4: 52.7;PC-3: 59.3;TIME: 55.9
76,FCGR3B,"CD16, CD16b, FCG3, FCGR3",ENSG00000162747,Fc fragment of IgG receptor IIIb,1,161623196-161631963,"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,appendix: 118.1;spleen: 115.2,urinary bladder: 36.3,Not detected,,
77,FCMR,"FAIM3, TOSO",ENSG00000162894,Fc fragment of IgM receptor,1,206904386-206923247,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA003910,Approved,,Approved,Nucleus<br>Focal adhesion sites<br>Cytosol,Breast cancer:4.23e-4 (favourable),Expressed in all,Tissue enhanced,,lymph node: 175.8;spleen: 148.0;tonsil: 146.7,appendix: 88.1,Group enriched,5.0,RPMI-8226: 97.7;U-266/70: 51.8
78,FCRL1,"CD307a, FCRH1, IFGP1, IRTA5",ENSG00000163534,Fc receptor like 1,1,157794403-157820105,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA013323,Enhanced,,,,,Mixed,Tissue enhanced,,lymph node: 30.3;spleen: 23.5;tonsil: 20.0,appendix: 12.5,Group enriched,31.0,Daudi: 3.7;U-698: 11.9
79,FCRL5,"BXMAS1, CD307e, FCRH5, IRTA2",ENSG00000143297,Fc receptor like 5,1,157513377-157552520,"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,lymph node: 28.7;spleen: 20.5;tonsil: 32.8,appendix: 17.9,Cell line enhanced,,U-266/70: 2.5;U-698: 5.1
80,FCRL6,"FcRH6, FLJ16056, IFGP6",ENSG00000181036,Fc receptor like 6,1,159800511-159816251,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,spleen: 18.4,lung: 8.9,Not detected,,
81,FGD2,ZFYVE4,ENSG00000146192,"FYVE, RhoGEF and PH domain containing 2",6,37005646-37029070,Predicted intracellular proteins,Evidence at protein level,"HPA029145, HPA049692",Approved,,,,,Mixed,Tissue enhanced,,spleen: 42.4,lymph node: 25.0,Group enriched,6.0,CAPAN-2: 2.4;Daudi: 8.2;HDLM-2: 10.5;U-698: 6.3
82,FGR,"c-fgr, p55c-fgr, SRC2",ENSG00000000938,"FGR proto-oncogene, Src family tyrosine kinase",1,27612064-27635277,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002024,Enhanced,,Approved,Plasma membrane<br>Aggresome,,Expressed in all,Tissue enhanced,,appendix: 85.6;bone marrow: 137.0;spleen: 90.6,lung: 56.3,Cell line enhanced,,Daudi: 61.4;HMC-1: 25.8;U-266/70: 116.7
83,FHOD1,FHOS,ENSG00000135723,Formin homology 2 domain containing 1,16,67229387-67247658,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA024468,Approved,,Supported,Cytosol,"Renal cancer:1.90e-8 (unfavourable), Cervical cancer:9.57e-4 (unfavourable)",Expressed in all,Tissue enhanced,,spleen: 62.3,skeletal muscle: 40.4,Expressed in all,,
84,FLI1,"EWSR2, SIC-1",ENSG00000151702,"Fli-1 proto-oncogene, ETS transcription factor",11,128686535-128813267,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA073099,,,Supported,Nucleus<br>Nuclear bodies,Renal cancer:4.60e-4 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 46.1,placenta: 15.6,Cell line enhanced,,HEL: 93.0;HUVEC TERT2: 46.8;REH: 44.4;TIME: 47.8
85,FLT3,"CD135, FLK2, STK1",ENSG00000122025,Fms related tyrosine kinase 3,13,28003274-28100592,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA047539,,,Approved,Endoplasmic reticulum,,Tissue enhanced,Tissue enhanced,,lymph node: 7.0;spleen: 7.7,appendix: 3.9,Group enriched,14.0,REH: 38.7;THP-1: 17.4
86,FRZB,"FRE, FRITZ, FRP-3, FRZB-1, FRZB-PEN, FRZB1, FZRB, hFIZ, SFRP3, SRFP3",ENSG00000162998,Frizzled-related protein,2,182833275-182867162,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:8.97e-6 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 101.2,gallbladder: 50.3,Cell line enhanced,,AF22: 16.2;ASC diff: 5.3;NTERA-2: 6.7;SH-SY5Y: 6.0
87,FUT7,,ENSG00000180549,Fucosyltransferase 7,9,137030174-137033010,Predicted intracellular proteins,Evidence at protein level,HPA042780,,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,lymph node: 3.7;spleen: 2.6,"bone marrow,tonsil: 2.0",Group enriched,7.0,NB-4: 10.4;THP-1: 14.0;U-937: 9.1
88,FYB,"FYB-120/130, SLAP-130",ENSG00000082074,FYN binding protein,5,39105236-39274528,Predicted intracellular proteins,Evidence at protein level,"CAB025336, HPA026796",Enhanced,,,,Renal cancer:2.24e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 127.4;lymph node: 109.8;spleen: 114.9,tonsil: 64.3,Cell line enhanced,,HEL: 61.3;MOLT-4: 171.5;REH: 58.5;U-937: 68.8
89,FZD8,,ENSG00000177283,Frizzled class receptor 8,10,35638249-35642278,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA045025, HPA071142",Approved,,Approved,Endoplasmic reticulum,Pancreatic cancer:8.21e-4 (favourable),Expressed in all,Tissue enhanced,,spleen: 15.9,lung: 6.6,Cell line enhanced,,PC-3: 37.6;U-138 MG: 14.7
90,GDF3,,ENSG00000184344,Growth differentiation factor 3,12,7689782-7695776,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA018468,Uncertain,,,,,Tissue enriched,Tissue enhanced,,kidney: 1.1;spleen: 1.1,testis: 0.8,Cell line enriched,14.0,NTERA-2: 450.4
91,GDPD2,"FLJ20207, GDE3, OBDPF",ENSG00000130055,Glycerophosphodiester phosphodiesterase domain containing 2,X,70423031-70433390,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,skin: 50.8;spleen: 60.0,small intestine: 20.0,Group enriched,8.0,AF22: 8.8;NTERA-2: 19.3
92,GDPD5,"GDE2, PP1665",ENSG00000158555,Glycerophosphodiester phosphodiesterase domain containing 5,11,75434640-75525903,Predicted membrane proteins,Evidence at protein level,"HPA065257, HPA066762, HPA069281",Uncertain,,Approved,Golgi apparatus,"Renal cancer:6.59e-9 (unfavourable), Endometrial cancer:1.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,,spleen: 67.0,testis: 31.2,Cell line enhanced,,HDLM-2: 62.5
93,GIMAP1,"HIMAP1, IAN2, IMAP1, IMAP38",ENSG00000213203,"GTPase, IMAP family member 1",7,150716557-150724284,Predicted membrane proteins,Evidence at protein level,"HPA044887, HPA053441",Uncertain,,Supported,Endoplasmic reticulum,"Liver cancer:1.09e-4 (favourable), Testis cancer:6.12e-4 (unfavourable)",Expressed in all,Tissue enhanced,,spleen: 32.8,lymph node: 21.3,Group enriched,10.0,HUVEC TERT2: 12.1;MOLT-4: 7.0;TIME: 3.1
94,GIMAP1-GIMAP5,,ENSG00000281887,GIMAP1-GIMAP5 readthrough,7,150716668-150743646,Predicted membrane proteins,Evidence at protein level,HPA053441,,,Supported,Endoplasmic reticulum,,Not detected,Tissue enhanced,,spleen: 17.9,appendix: 14.9,Group enriched,9.0,HUVEC TERT2: 5.3;MOLT-4: 8.3;THP-1: 1.7;TIME: 3.9
95,GJD3,"Cx30.2, CX31.9, GJA11, GJC1",ENSG00000183153,Gap junction protein delta 3,17,40362931-40363815,Predicted membrane proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,spleen: 7.0,stomach: 2.7,Cell line enhanced,,BEWO: 14.7
96,GNLY,"D2S69E, LAG-2, LAG2, NKG5, TLA519",ENSG00000115523,Granulysin,2,85685175-85698854,"Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB025186, HPA058021",Enhanced,,,,"Endometrial cancer:3.48e-5 (favourable), Melanoma:6.60e-5 (favourable), Renal cancer:1.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable)",Expressed in all,Tissue enhanced,,bone marrow: 152.4;endometrium: 113.5;spleen: 112.9,lung: 51.0,Not detected,,
97,GP9,"CD42a, GPIX",ENSG00000169704,Glycoprotein IX platelet,3,129060767-129062406,"CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA063182,Enhanced,,,,,Not detected,Tissue enhanced,,bone marrow: 2.9;spleen: 2.7,testis: 1.2,Cell line enriched,19.0,HEL: 75.1
98,GPR174,FKSG79,ENSG00000147138,G protein-coupled receptor 174,X,79170972-79172229,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA041025,Enhanced,,Uncertain,Vesicles,,Mixed,Tissue enhanced,,lymph node: 29.8;spleen: 16.7;tonsil: 17.2,appendix: 12.6,Cell line enriched,8.0,MOLT-4: 85.1
99,GPR182,"ADMR, AM-R, G10D, hrhAMR",ENSG00000166856,G protein-coupled receptor 182,12,56994446-56998441,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA027037,Enhanced,,,,,Not detected,Tissue enhanced,,spleen: 12.2;testis: 6.7,liver: 2.0,Cell line enhanced,,RH-30: 1.8
100,GPR55,,ENSG00000135898,G protein-coupled receptor 55,2,230907318-230961066,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,spleen: 5.8;testis: 9.0,tonsil: 4.4,Cell line enhanced,,HDLM-2: 6.0;Karpas-707: 23.3;SK-MEL-30: 4.7
101,GPSM3,"AGS4, C6orf9, G18, G18.1a, G18.1b, G18.2, NG1",ENSG00000213654,G-protein signaling modulator 3,6,32190766-32195523,Predicted intracellular proteins,Evidence at protein level,,,,,,"Renal cancer:6.92e-9 (unfavourable), Endometrial cancer:5.98e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 27.5;spleen: 29.3,appendix: 24.9,Cell line enhanced,,HMC-1: 35.2;NB-4: 14.7;THP-1: 16.2
102,GRAP,,ENSG00000154016,GRB2-related adaptor protein,17,19020673-19047637,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA046595, HPA066654",Uncertain,,Approved,Centrosome,,Mixed,Tissue enhanced,,lymph node: 30.9;spleen: 25.4,tonsil: 20.7,Group enriched,5.0,Daudi: 52.5;HUVEC TERT2: 24.8;MOLT-4: 12.3;REH: 35.4;TIME: 47.9;U-698: 35.4
103,GRAPL,,ENSG00000189152,GRB2 related adaptor protein like,17,19127469-19159176,Predicted intracellular proteins,Evidence at transcript level,"HPA051796, HPA066654",Uncertain,,Approved,Centrosome,,Not detected,Tissue enhanced,,lymph node: 26.7;spleen: 32.0,tonsil: 21.5,Group enriched,6.0,Daudi: 27.6;HUVEC TERT2: 13.0;TIME: 34.3;U-698: 24.5
104,GRIN3B,GluN3B,ENSG00000116032,Glutamate ionotropic receptor NMDA type subunit 3B,19,1000419-1009732,"FDA approved drug targets, Predicted membrane proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,fallopian tube: 2.1;spleen: 1.2,lung: 0.7,Cell line enhanced,,U-266/70: 2.6
105,GSDMC,MLZE,ENSG00000147697,Gasdermin C,8,129748196-129786888,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA023670, HPA024767, HPA026317",Supported,,Enhanced,Mitochondria,,Group enriched,Tissue enhanced,,esophagus: 20.0;skin: 44.3;spleen: 21.6,tonsil: 6.5,Cell line enhanced,,A-431: 13.0;HaCaT: 3.1;hTCEpi: 4.5;HUVEC TERT2: 5.2;TIME: 4.3
106,GZMH,"CCP-X, CGL-2, CSP-C, CTLA1, CTSGL2",ENSG00000100450,Granzyme H,14,24606480-24609699,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA029200,Enhanced,,,,"Renal cancer:1.74e-6 (unfavourable), Endometrial cancer:2.00e-6 (favourable)",Expressed in all,Tissue enhanced,,spleen: 35.3,lymph node: 25.3,Not detected,,
107,GZMM,"LMET1, MET1",ENSG00000197540,Granzyme M,19,544034-549924,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA015624,Enhanced,,,,"Head and neck cancer:1.87e-7 (favourable), Renal cancer:1.21e-4 (unfavourable), Endometrial cancer:1.89e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 20.9;spleen: 19.7,appendix: 13.0,Cell line enhanced,,EFO-21: 1.9;HDLM-2: 1.6;HMC-1: 1.8;MOLT-4: 1.1
108,HCAR2,"GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG",ENSG00000182782,Hydroxycarboxylic acid receptor 2,12,122701293-122703343,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA028660,Approved,,Approved,Cell Junctions,,Group enriched,Tissue enhanced,,spleen: 36.0,esophagus: 25.5,Cell line enriched,7.0,HaCaT: 105.3
109,HCAR3,"GPR109B, HCA3, HM74",ENSG00000255398,Hydroxycarboxylic acid receptor 3,12,122714756-122716892,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA028660,Approved,,Approved,Cell Junctions,,Mixed,Tissue enhanced,,bone marrow: 16.6;spleen: 21.7,appendix: 12.4,Group enriched,6.0,HaCaT: 8.1;RT4: 28.3
110,HCK,JTK9,ENSG00000101336,"HCK proto-oncogene, Src family tyrosine kinase",20,32052188-32101856,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005195, HPA063768",Approved,,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:1.66e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 149.6;spleen: 113.2,lung: 74.1,Group enriched,8.0,THP-1: 48.4;U-937: 161.1
111,HIST2H3PS2,p06,ENSG00000203818,Histone cluster 2 H3 pseudogene 2,1,143905556-143905966,Predicted intracellular proteins,Evidence at protein level,HPA042570,Supported,,,,,Not detected,Tissue enhanced,,adrenal gland: 8.5;spleen: 7.7,ovary: 5.8,Cell line enhanced,,BJ: 6.7;NB-4: 5.8;SH-SY5Y: 10.0;THP-1: 6.3;U-2197: 6.2
112,HLA-DOA,"HLA-D0-alpha, HLA-DNA, HLA-DZA",ENSG00000204252,"Major histocompatibility complex, class II, DO alpha",6,33004178-33009612,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA045038,Enhanced,,,,,Expressed in all,Tissue enhanced,,spleen: 14.4,tonsil: 8.9,Cell line enhanced,,Daudi: 4.6;HDLM-2: 4.3;REH: 19.0;U-698: 3.4
113,HS3ST3A1,"30ST3A1, 3OST3A1",ENSG00000153976,Heparan sulfate-glucosamine 3-sulfotransferase 3A1,17,13495689-13601927,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA062518, HPA071530",Uncertain,,Approved,Microtubules,,Mixed,Tissue enhanced,,spleen: 9.1,seminal vesicle: 6.8,Cell line enhanced,,PC-3: 40.6;U-251 MG: 103.1;U-87 MG: 72.4
114,HYAL1,"FUS2, HYAL-1, LUCA1, NAT6",ENSG00000114378,Hyaluronoglucosaminidase 1,3,50299889-50312381,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA002112,Uncertain,,,,"Renal cancer:1.56e-11 (favourable), Colorectal cancer:2.07e-4 (favourable)",Expressed in all,Tissue enhanced,,liver: 71.1;spleen: 69.3,kidney: 43.5,Cell line enhanced,,Hep G2: 66.6;SK-BR-3: 20.5
115,IGSF21,"MGC15730, RP11-121A23.1",ENSG00000117154,Immunoglobin superfamily member 21,1,18107746-18378483,Predicted secreted proteins,Evidence at protein level,HPA044535,Approved,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 28.9;spleen: 13.2,adrenal gland: 5.9,Cell line enriched,6.0,SCLC-21H: 21.2
116,IGSF6,DORA,ENSG00000140749,Immunoglobulin superfamily member 6,16,21639537-21652660,Predicted membrane proteins,Evidence at protein level,"HPA041023, HPA041072",Uncertain,,,,"Endometrial cancer:1.54e-5 (favourable), Cervical cancer:4.92e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 15.2;spleen: 18.1,lung: 8.0,Not detected,,
117,IKZF3,"Aiolos, ZNFN1A3",ENSG00000161405,IKAROS family zinc finger 3,17,39757715-39864188,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB017105, HPA024377",Enhanced,,Uncertain,Plasma membrane<br>Cytosol,"Cervical cancer:6.85e-6 (favourable), Head and neck cancer:4.16e-4 (favourable), Melanoma:5.42e-4 (favourable), Renal cancer:7.38e-4 (unfavourable)",Mixed,Tissue enhanced,,lymph node: 44.7;spleen: 31.7;tonsil: 39.2,appendix: 25.5,Cell line enhanced,,Daudi: 50.3;Karpas-707: 25.9;U-266/70: 32.8;U-266/84: 35.9;U-698: 78.2
118,IL10RA,"CD210, CD210a, CDW210A, HIL-10R, IL10R",ENSG00000110324,Interleukin 10 receptor subunit alpha,11,117986348-118003037,"CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,,,,,,"Renal cancer:1.45e-5 (unfavourable), Head and neck cancer:4.47e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 86.2,lymph node: 56.0,Cell line enhanced,,Daudi: 21.3;HDLM-2: 69.7;Karpas-707: 19.5;RPMI-8226: 23.7
119,IL18BP,IL18BPa,ENSG00000137496,Interleukin 18 binding protein,11,71998541-72005715,Predicted secreted proteins,Evidence at protein level,"CAB025980, HPA041061",Enhanced,,Approved,Endoplasmic reticulum,Renal cancer:2.93e-6 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 56.2,appendix: 32.8,Mixed,,
120,IL24,"C49A, FISP, IL-24, IL10B, mda-7, Mob-5, ST16",ENSG00000162892,Interleukin 24,1,206897443-206904139,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB025972,Uncertain,,,,Breast cancer:5.09e-4 (favourable),Mixed,Tissue enhanced,,appendix: 17.3;lymph node: 37.1;spleen: 23.4,urinary bladder: 5.4,Cell line enriched,10.0,BJ hTERT+: 144.5
121,IL2RB,"CD122, IL15RB",ENSG00000100385,Interleukin 2 receptor subunit beta,22,37125838-37175054,"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA062657,Enhanced,,,,"Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 52.7;spleen: 67.1,lymph node: 39.8,Cell line enriched,10.0,HDLM-2: 476.9
122,IL34,"C16orf77, IL-34, MGC34647",ENSG00000157368,Interleukin 34,16,70579895-70660682,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:3.52e-8 (unfavourable), Cervical cancer:7.41e-4 (favourable), Head and neck cancer:9.69e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 58.0;spleen: 145.6,cerebral cortex: 20.8,Cell line enhanced,,NTERA-2: 5.5;U-138 MG: 3.5
123,IRF8,"ICSBP, ICSBP1, IRF-8",ENSG00000140968,Interferon regulatory factor 8,16,85898803-85922609,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA002267, HPA002531, CAB013480",Enhanced,,Enhanced,Nucleoplasm,,Expressed in all,Tissue enhanced,,lymph node: 297.7;spleen: 205.7;tonsil: 232.5,appendix: 118.0,Cell line enhanced,,Daudi: 177.0;THP-1: 280.9;U-698: 672.1;U-937: 108.3
124,ITGA4,CD49D,ENSG00000115232,Integrin subunit alpha 4,2,181457202-181536187,"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA074961,,,Approved,Plasma membrane,"Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable)",Mixed,Tissue enhanced,,spleen: 67.6,appendix: 49.6,Cell line enhanced,,fHDF/TERT166: 148.2;HEL: 275.3;MOLT-4: 291.8
125,ITGAL,"CD11A, LFA-1",ENSG00000005844,Integrin subunit alpha L,16,30472658-30523185,"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB025011,Enhanced,,,,"Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 79.0;spleen: 80.9,appendix: 52.5,Cell line enriched,5.0,HMC-1: 570.1
126,ITGAX,CD11C,ENSG00000140678,Integrin subunit alpha X,16,31355134-31382997,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB004458, HPA004723, CAB072871",Enhanced,,,,Renal cancer:1.37e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 58.3;spleen: 59.0,bone marrow: 30.4,Cell line enriched,5.0,HMC-1: 92.2
127,KANK3,"ANKRD47, FLJ46061",ENSG00000186994,KN motif and ankyrin repeat domains 3,19,8322584-8343262,Predicted intracellular proteins,Evidence at protein level,HPA051153,Approved,,Approved,Plasma membrane,Renal cancer:1.69e-5 (favourable),Expressed in all,Tissue enhanced,,spleen: 24.9,adipose tissue: 22.2,Cell line enhanced,,HUVEC TERT2: 6.8;TIME: 12.1;U-266/70: 4.5
128,KAZALD1,"FKSG28, FKSG40",ENSG00000107821,Kazal type serine peptidase inhibitor domain 1,10,101061841-101068131,Predicted secreted proteins,Evidence at protein level,HPA011800,Uncertain,,,,Thyroid cancer:5.10e-4 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 26.8,"cervix, uterine: 15.7",Cell line enhanced,,AN3-CA: 35.1;T-47d: 45.4
129,KAZN,"FLJ43806, KAZRIN, KIAA1026",ENSG00000189337,"Kazrin, periplakin interacting protein",1,13892792-15118043,Predicted intracellular proteins,Evidence at protein level,"HPA032095, HPA032096",Approved,,Supported,Nucleoplasm<br>Nuclear speckles<br>Cytosol,Renal cancer:1.20e-6 (favourable),Mixed,Tissue enhanced,,spleen: 118.3,parathyroid gland: 42.3,Cell line enhanced,,AN3-CA: 79.3
130,KCNB2,Kv2.2,ENSG00000182674,Potassium voltage-gated channel subfamily B member 2,8,72537391-72938349,"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA065970,,,Approved,Nucleoli<br>Plasma membrane<br>Midbody,,Not detected,Tissue enhanced,,cerebral cortex: 3.2;spleen: 3.3,"fallopian tube,testis: 0.7",Cell line enhanced,,HaCaT: 1.3;HDLM-2: 1.4;HEK93: 3.2;SCLC-21H: 3.4
131,KIF19,"FLJ37300, KIF19A",ENSG00000196169,Kinesin family member 19,17,74326210-74355820,Predicted intracellular proteins,Evidence at protein level,"HPA043638, HPA073303",Enhanced,,Approved,Plasma membrane<br>Actin filaments<br>Centrosome,,Mixed,Tissue enhanced,,fallopian tube: 19.0;spleen: 6.6,duodenum: 2.9,Cell line enriched,13.0,SCLC-21H: 5.1
132,KLRC3,NKG2-E,ENSG00000205810,Killer cell lectin like receptor C3,12,10412312-10420595,Predicted membrane proteins,Evidence at transcript level,"HPA039910, HPA062570",Approved,,Uncertain,Vesicles,,Tissue enriched,Tissue enhanced,,cerebral cortex: 9.2;spleen: 6.2,lymph node: 2.3,Cell line enhanced,,HEL: 1.1;HeLa: 4.5;U-698: 1.3
133,KLRC4,NKG2-F,ENSG00000183542,Killer cell lectin like receptor C4,12,10407382-10409757,Predicted membrane proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,spleen: 13.1,lymph node: 5.6,Cell line enhanced,,HeLa: 3.1;U-698: 1.1
134,KLRD1,CD94,ENSG00000134539,Killer cell lectin like receptor D1,12,10226058-10329600,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA069688,Uncertain,,,,,Mixed,Tissue enhanced,,spleen: 18.8,lymph node: 6.7,Mixed,,
135,KLRF1,"CLEC5C, NKp80",ENSG00000150045,Killer cell lectin like receptor F1,12,9827481-9845007,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,spleen: 24.9,bone marrow: 7.2,Cell line enhanced,,BJ hTERT+: 1.2;HAP1: 1.4;U-937: 3.5
136,KLRG1,"2F1, CLEC15A, MAFA, MAFA-L",ENSG00000139187,Killer cell lectin like receptor G1,12,8950044-9010760,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA051403, HPA076494",,,Supported,Vesicles,,Mixed,Tissue enhanced,,spleen: 15.8,lymph node: 13.5,Cell line enhanced,,HEL: 29.9;NTERA-2: 22.2;U-937: 16.1
137,KLRK1,"CD314, D12S2489E, KLR, NKG2-D, NKG2D",ENSG00000213809,Killer cell lectin like receptor K1,12,10372353-10391874,"Cancer-related genes, CD markers, Predicted membrane proteins",Evidence at protein level,"CAB021896, HPA068877",Enhanced,,Supported,Plasma membrane,,Not detected,Tissue enhanced,,lymph node: 35.1;spleen: 52.8,tonsil: 16.2,Cell line enriched,8.0,U-698: 41.6
138,LAG3,CD223,ENSG00000089692,Lymphocyte activating 3,12,6772512-6778455,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002301, HPA013967",Enhanced,,,,"Renal cancer:4.62e-11 (unfavourable), Cervical cancer:3.89e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 32.0,lymph node: 17.6,Cell line enriched,140.0,HDLM-2: 136.0
139,LENG1,,ENSG00000105617,Leukocyte receptor cluster member 1,19,54155161-54159882,Predicted intracellular proteins,Evidence at protein level,HPA043541,Uncertain,,Approved,Nucleus<br>Plasma membrane,"Renal cancer:3.72e-4 (favourable), Pancreatic cancer:8.12e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 1.8,endometrium: 1.0,Cell line enhanced,,AF22: 3.2;HaCaT: 4.1;HDLM-2: 2.8;LHCN-M2: 2.3;U-87 MG: 3.1
140,LILRA2,"CD85h, ILT1, LIR-7, LIR7",ENSG00000239998,Leukocyte immunoglobulin like receptor A2,19,54572920-54590287,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,bone marrow: 9.9;spleen: 7.0,appendix: 4.0,Cell line enhanced,,REH: 1.8;THP-1: 2.7;U-937: 7.1
141,LILRA4,"CD85g, ILT7",ENSG00000239961,Leukocyte immunoglobulin like receptor A4,19,54333185-54339150,"CD markers, Predicted membrane proteins",Evidence at protein level,HPA049418,Approved,,,,,Mixed,Tissue enhanced,,spleen: 2.1;tonsil: 2.5,lymph node: 0.9,Not detected,,
142,LILRA5,"CD85, CD85f, ILT11, LILRB7, LIR9",ENSG00000187116,Leukocyte immunoglobulin like receptor A5,19,54307070-54313139,"CD markers, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:7.78e-4 (unfavourable),Mixed,Tissue enhanced,,appendix: 13.9;bone marrow: 10.3;spleen: 7.5,urinary bladder: 2.4,Not detected,,
143,LILRA6,"CD85b, ILT8, LILRB6",ENSG00000244482,Leukocyte immunoglobulin like receptor A6,19,54236592-54242791,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,adipose tissue: 1.9;appendix: 1.9;smooth muscle: 1.9;spleen: 1.9,bone marrow: 1.0,Not detected,,
144,LILRB1,"CD85, CD85j, ILT2, LIR-1, LIR1, MIR-7, PIR-B, PIRB",ENSG00000104972,Leukocyte immunoglobulin like receptor B1,19,54617158-54637528,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:3.08e-6 (unfavourable),Mixed,Tissue enhanced,,appendix: 8.6;lymph node: 6.2;spleen: 9.9,smooth muscle: 3.7,Group enriched,17.0,Daudi: 4.0;THP-1: 1.9
145,LILRB2,"CD85d, ILT4, LIR-2, LIR2, MIR-10, MIR10",ENSG00000131042,Leukocyte immunoglobulin like receptor B2,19,54273821-54281184,"CD markers, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:5.45e-7 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 8.7;bone marrow: 20.5;spleen: 10.4,lung: 3.9,Not detected,,
146,LILRB5,"CD85c, LIR-8, LIR8",ENSG00000105609,Leukocyte immunoglobulin like receptor B5,19,54249431-54257301,"CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA012069,Approved,,,,,Mixed,Tissue enhanced,,spleen: 26.1,adipose tissue: 11.4,Not detected,,
147,LINGO3,"LERN2, LRRN6B",ENSG00000220008,Leucine rich repeat and Ig domain containing 3,19,2289784-2292024,Predicted membrane proteins,Evidence at protein level,"HPA043781, HPA055932, HPA059558",Uncertain,,Approved,Mitochondria,,Tissue enhanced,Tissue enhanced,,appendix: 1.6;cerebral cortex: 1.6;spleen: 3.7,lymph node: 1.2,Group enriched,6.0,HMC-1: 15.2;RPMI-8226: 3.0
148,LMAN1L,"ERGIC-53L, ERGL",ENSG00000140506,"Lectin, mannose binding 1 like",15,74812716-74825758,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,prostate: 91.3;spleen: 31.7,heart muscle: 12.7,Not detected,,
149,LPCAT1,"AGPAT10, AGPAT9, AYTL2, FLJ12443",ENSG00000153395,Lysophosphatidylcholine acyltransferase 1,5,1456480-1523977,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA012501, HPA022268",Enhanced,,Supported,Endoplasmic reticulum<br>Lipid droplets,"Liver cancer:1.88e-8 (unfavourable), Renal cancer:2.64e-7 (unfavourable), Pancreatic cancer:4.90e-5 (favourable), Cervical cancer:7.11e-5 (unfavourable), Endometrial cancer:3.67e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lung: 19.0;spleen: 14.7,cerebral cortex: 4.4,Cell line enhanced,,BEWO: 80.0;EFO-21: 74.7;PC-3: 52.0
150,LRRC25,"FLJ38116, MAPA",ENSG00000175489,Leucine rich repeat containing 25,19,18391144-18397617,Predicted membrane proteins,Evidence at protein level,HPA029459,Approved,,,,Testis cancer:6.93e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 30.4;spleen: 40.6,bone marrow: 20.7,Cell line enhanced,,HMC-1: 1.6;THP-1: 1.2;U-937: 1.1
151,LRTM1,HT017,ENSG00000144771,Leucine rich repeats and transmembrane domains 1,3,54918237-54967088,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,skeletal muscle: 9.3;spleen: 8.9,esophagus: 4.3,Cell line enhanced,,HEL: 1.0
152,LST1,"B144, D6S49E, LST-1",ENSG00000204482,Leukocyte specific transcript 1,6,31586124-31588909,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:5.97e-5 (unfavourable), Testis cancer:7.62e-4 (unfavourable), Cervical cancer:7.89e-4 (favourable)",Expressed in all,Tissue enhanced,,bone marrow: 68.7;spleen: 48.9,appendix: 32.1,Cell line enhanced,,HMC-1: 64.7;NB-4: 50.8;THP-1: 128.8;U-937: 79.6
153,LY9,"CD229, hly9, mLY9, SLAMF3",ENSG00000122224,Lymphocyte antigen 9,1,160796074-160828261,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA050917,Approved,,,,,Mixed,Tissue enhanced,,lymph node: 34.5;spleen: 28.2;tonsil: 28.3,appendix: 17.8,Cell line enhanced,,Daudi: 10.2;Karpas-707: 20.1;U-266/70: 53.8;U-266/84: 20.4
154,LYL1,bHLHa18,ENSG00000104903,"LYL1, basic helix-loop-helix family member",19,13099033-13103161,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA075004,,,Approved,Golgi apparatus,Renal cancer:3.89e-4 (unfavourable),Expressed in all,Tissue enhanced,,bone marrow: 22.9;spleen: 20.7,appendix: 14.3,Cell line enhanced,,HEL: 113.5;HMC-1: 179.8;K-562: 90.4;NB-4: 82.5;REH: 87.2
155,LYN,JTK8,ENSG00000254087,"LYN proto-oncogene, Src family tyrosine kinase",8,55879813-56014168,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001231, CAB004492",Enhanced,,Supported,Golgi apparatus<br>Vesicles<br>Plasma membrane,Renal cancer:3.43e-4 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 161.1,appendix: 130.6,Cell line enhanced,,HEL: 215.0;HMC-1: 205.1
156,MADCAM1,MACAM1,ENSG00000099866,Mucosal vascular addressin cell adhesion molecule 1,19,489176-505342,Predicted membrane proteins,Evidence at protein level,CAB075699,Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 17.8;spleen: 11.4,gallbladder: 3.3,Mixed,,
157,MAP4K1,HPK1,ENSG00000104814,Mitogen-activated protein kinase kinase kinase kinase 1,19,38587641-38618882,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007419, CAB007754",Enhanced,,Uncertain,Nucleoplasm<br>Plasma membrane,"Renal cancer:7.99e-10 (unfavourable), Cervical cancer:6.17e-5 (favourable), Head and neck cancer:3.26e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 37.3;spleen: 23.8;tonsil: 27.2,appendix: 19.2,Cell line enhanced,,Daudi: 34.0;HDLM-2: 44.1;Karpas-707: 34.0;U-266/70: 28.3;U-266/84: 27.3;U-698: 41.0
158,MEFV,"FMF, MEF, TRIM20",ENSG00000103313,"MEFV, pyrin innate immunity regulator",16,3242028-3256627,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,appendix: 8.1;spleen: 7.0,bone marrow: 4.2,Cell line enhanced,,THP-1: 4.4
159,MMP25,"MMP20, MMPL1, MT6-MMP",ENSG00000008516,Matrix metallopeptidase 25,16,3046681-3060726,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB025177,Uncertain,,,,Head and neck cancer:1.09e-5 (favourable),Tissue enhanced,Tissue enhanced,,appendix: 23.3;bone marrow: 24.7;spleen: 20.7,adipose tissue: 6.4,Cell line enriched,11.0,HMC-1: 95.7
160,MNDA,PYHIN3,ENSG00000163563,Myeloid cell nuclear differentiation antigen,1,158831317-158849506,Predicted intracellular proteins,Evidence at protein level,"HPA034532, HPA073215",Enhanced,,Supported,Nucleoplasm<br>Nucleoli,,Expressed in all,Tissue enhanced,,bone marrow: 194.8;spleen: 144.9,appendix: 111.3,Group enriched,13.0,NB-4: 93.3;THP-1: 185.6;U-937: 141.2
161,MPEG1,MPG1,ENSG00000197629,Macrophage expressed 1,11,59208510-59212951,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA046801,Approved,,,,,Expressed in all,Tissue enhanced,,spleen: 283.2,appendix: 152.1,Not detected,,
162,MS4A7,"CD20L4, CFFM4, MS4A8",ENSG00000166927,Membrane spanning 4-domains A7,11,60378482-60395951,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA017418, CAB026387",Approved,,,,,Expressed in all,Tissue enhanced,,spleen: 316.0,lung: 125.0,Cell line enriched,25.0,THP-1: 78.2
163,MYCT1,"FLJ21269, MTLC",ENSG00000120279,Myc target 1,6,152697895-152724567,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA047992,,,Uncertain,Nucleoplasm,Renal cancer:4.73e-4 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 69.0,placenta: 29.9,Cell line enhanced,,HEL: 20.7;HUVEC TERT2: 103.9;TIME: 85.0
164,MYO1F,,ENSG00000142347,Myosin IF,19,8520790-8577577,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA055242,Enhanced,,,,Renal cancer:3.27e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 50.4;bone marrow: 59.7;spleen: 63.3,lung: 23.4,Cell line enhanced,,HDLM-2: 45.8;HMC-1: 73.1;NB-4: 127.9;THP-1: 99.8;U-937: 61.8
165,MYO1G,HA-2,ENSG00000136286,Myosin IG,7,44962662-44979098,Predicted intracellular proteins,Evidence at protein level,HPA021252,Enhanced,,,,"Renal cancer:8.71e-8 (unfavourable), Cervical cancer:8.26e-4 (favourable)",Expressed in all,Tissue enhanced,,bone marrow: 27.7;lymph node: 27.7;spleen: 24.6,appendix: 21.9,Cell line enhanced,,HDLM-2: 53.6;HEL: 62.4;HL-60: 31.8;MOLT-4: 71.7;THP-1: 52.2;U-937: 44.7
166,NCF1,"NCF1A, NOXO2, p47phox, SH3PXD1A",ENSG00000158517,Neutrophil cytosolic factor 1,7,74773962-74789315,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB004524, HPA047836, HPA052095",Enhanced,,,,,Mixed,Tissue enhanced,,lymph node: 71.2;spleen: 74.1,bone marrow: 60.9,Group enriched,6.0,Daudi: 72.6;HMC-1: 122.5
167,NCR3,"1C7, CD337, LY117, NKp30",ENSG00000204475,Natural cytotoxicity triggering receptor 3,6,31588895-31592985,"CD markers, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,lymph node: 1.7;spleen: 1.5;tonsil: 1.1,appendix: 1.0,Cell line enhanced,,NB-4: 2.6
168,NDST3,HSST3,ENSG00000164100,N-deacetylase and N-sulfotransferase 3,4,118033618-118258648,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA056189,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 3.0;spleen: 2.8,"cervix, uterine: 0.7",Cell line enriched,16.0,MOLT-4: 13.3
169,NETO2,"FLJ10430, NEOT2",ENSG00000171208,Neuropilin and tolloid like 2,16,47077703-47143997,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA013180,Uncertain,,Approved,Golgi apparatus,Renal cancer:5.53e-6 (unfavourable),Mixed,Tissue enhanced,,spleen: 31.5,cerebral cortex: 20.9,Mixed,,
170,NKG7,"GIG1, GMP-17",ENSG00000105374,Natural killer cell granule protein 7,19,51371606-51372715,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA071454,,,Approved,Vesicles,"Renal cancer:3.32e-6 (unfavourable), Endometrial cancer:7.42e-6 (favourable)",Expressed in all,Tissue enhanced,,bone marrow: 351.3;spleen: 151.2,lymph node: 122.0,Cell line enhanced,,NB-4: 109.5;THP-1: 34.5;U-937: 34.9
171,NKX2-3,"CSX3, NKX2.3, NKX2C, NKX4-3",ENSG00000119919,NK2 homeobox 3,10,99532933-99536524,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA047561,Uncertain,,Uncertain,Nucleoli<br>Cytosol,,Tissue enhanced,Tissue enhanced,,small intestine: 12.7;spleen: 29.6,duodenum: 11.5,Cell line enhanced,,NB-4: 1.1;REH: 2.0
172,NKX3-2,"BAPX1, NKX3.2, NKX3B",ENSG00000109705,NK3 homeobox 2,4,13540830-13545050,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA027564,Approved,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,spleen: 2.7,smooth muscle: 1.6,Cell line enhanced,,HAP1: 3.6;NB-4: 6.2;NTERA-2: 5.3;THP-1: 3.9
173,NOX5,"NOX5A, NOX5B",ENSG00000255346,NADPH oxidase 5,15,68930525-69062743,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,spleen: 13.2,testis: 3.5,Not detected,,
174,NPY1R,NPYR,ENSG00000164128,Neuropeptide Y receptor Y1,4,163323961-163344832,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029903,,,Approved,Nucleus<br>Mitochondria<br>Cytosol,Breast cancer:7.68e-5 (favourable),Tissue enriched,Tissue enhanced,,spleen: 151.8,breast: 39.6,Cell line enriched,16.0,HEL: 105.6
175,NPY5R,NPYR5,ENSG00000164129,Neuropeptide Y receptor Y5,4,163343939-163351934,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,spleen: 12.3;testis: 9.7,adipose tissue: 7.7,Not detected,,
176,NTN4,,ENSG00000074527,Netrin 4,12,95657807-95791152,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049832,Approved,,,,"Renal cancer:8.12e-9 (favourable), Urothelial cancer:6.67e-5 (favourable), Pancreatic cancer:9.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,,spleen: 246.4,kidney: 118.6,Cell line enhanced,,BJ hTERT+: 407.7;TIME: 235.1
177,OR1L8,,ENSG00000171496,Olfactory receptor family 1 subfamily L member 8,9,122567548-122568477,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,spleen: 1.2,testis: 0.8,Cell line enriched,7.0,RT4: 5.5
178,P2RY10,P2Y10,ENSG00000078589,Purinergic receptor P2Y10,X,78945332-78961954,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA036757, HPA065766",Enhanced,,,,Renal cancer:3.63e-4 (unfavourable),Mixed,Tissue enhanced,,lymph node: 33.1;spleen: 22.6;tonsil: 24.0,appendix: 19.4,Group enriched,5.0,Karpas-707: 90.1;U-266/70: 20.1
179,P2RY13,"FKSG77, GPR86, GPR94, P2Y13",ENSG00000181631,Purinergic receptor P2Y13,3,151326312-151329548,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA049047,Enhanced,,,,,Expressed in all,Tissue enhanced,,spleen: 51.2,appendix: 27.9,Not detected,,
180,P2RY6,P2Y6,ENSG00000171631,Pyrimidinergic receptor P2Y6,11,73264505-73298617,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,CAB022740,Uncertain,,,,Renal cancer:2.50e-7 (unfavourable),Mixed,Tissue enhanced,,placenta: 16.8;spleen: 35.6,appendix: 10.8,Cell line enhanced,,AN3-CA: 64.0;EFO-21: 20.2;MCF7: 25.4;SK-BR-3: 41.5
181,PARP15,"FLJ40597, pART7",ENSG00000173200,Poly(ADP-ribose) polymerase family member 15,3,122577602-122639047,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA035757,,,Approved,Mitochondria,,Mixed,Tissue enhanced,,lymph node: 55.0;spleen: 60.4;tonsil: 48.1,appendix: 35.3,Cell line enhanced,,HEL: 7.8;TIME: 8.4
182,PARVG,,ENSG00000138964,Parvin gamma,22,44172956-44219533,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA031833, HPA031834",Uncertain,,,,"Renal cancer:3.43e-6 (unfavourable), Endometrial cancer:4.44e-6 (favourable)",Expressed in all,Tissue enhanced,,spleen: 38.4,appendix: 35.4,Cell line enhanced,,HL-60: 92.2;NB-4: 28.2;THP-1: 43.6;U-937: 42.1
183,PATL2,Pat1a,ENSG00000229474,PAT1 homolog 2,15,44665732-44711316,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,lymph node: 20.0;spleen: 19.3,appendix: 10.4,Cell line enriched,30.0,U-266/70: 95.9
184,PAX5,BSAP,ENSG00000196092,Paired box 5,9,36833275-37034185,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB026269, CAB026869, HPA056394, HPA068498",Enhanced,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,,Mixed,Tissue enhanced,,lymph node: 48.5;spleen: 26.2;tonsil: 33.2,appendix: 19.5,Group enriched,6.0,Daudi: 48.5;REH: 181.0;U-698: 61.2
185,PCDH17,"PCDH68, PCH68",ENSG00000118946,Protocadherin 17,13,57631810-57729311,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA026817,Uncertain,,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Renal cancer:3.31e-5 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 25.8;spleen: 33.8,lung: 18.3,Cell line enhanced,,AF22: 13.8;HEK93: 8.1;U-87 MG: 5.1
186,PCSK6,"PACE4, SPC4",ENSG00000140479,Proprotein convertase subtilisin/kexin type 6,15,101297142-101525202,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004774,Uncertain,,,,"Renal cancer:7.06e-7 (unfavourable), Breast cancer:9.99e-4 (favourable)",Mixed,Tissue enhanced,,liver: 90.3;spleen: 124.6,placenta: 53.9,Cell line enhanced,,BEWO: 57.8;HEK93: 58.5;Hep G2: 39.9
187,PDCD1LG2,"B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2",ENSG00000197646,Programmed cell death 1 ligand 2,9,5510570-5571254,"Cancer-related genes, CD markers, Predicted membrane proteins",Evidence at protein level,HPA013411,Approved,,Approved,Cytosol,Renal cancer:1.15e-4 (unfavourable),Mixed,Tissue enhanced,,spleen: 21.5,lymph node: 12.0,Cell line enhanced,,BJ: 62.0;BJ hTERT+: 93.1;HDLM-2: 83.9
188,PDE2A,,ENSG00000186642,Phosphodiesterase 2A,11,72576141-72674591,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB009752, HPA031192",Enhanced,,Supported,Cytosol,Liver cancer:1.76e-6 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 141.8;spleen: 184.3,adipose tissue: 62.1,Cell line enriched,6.0,HeLa: 340.7
189,PDE6G,"PDEG, RP57",ENSG00000185527,Phosphodiesterase 6G,17,81650459-81663112,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA045118,Supported,,,,,Tissue enhanced,Tissue enhanced,,lymph node: 26.1;spleen: 33.3,placenta: 18.9,Cell line enhanced,,NTERA-2: 10.5;REH: 11.5
190,PF4V1,"CXCL4L1, CXCL4V1, SCYB4V1",ENSG00000109272,Platelet factor 4 variant 1,4,73853189-73854155,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA052485,Supported,,,,,Tissue enhanced,Tissue enhanced,,spleen: 3.9,urinary bladder: 2.8,Cell line enhanced,,CAPAN-2: 1.2;EFO-21: 2.0
191,PHOSPHO1,,ENSG00000173868,Phosphoethanolamine/phosphocholine phosphatase,17,49223362-49230766,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA053016, HPA065025",Uncertain,,Approved,Plasma membrane<br>Actin filaments,,Mixed,Tissue enhanced,,spleen: 20.4;testis: 41.1,bone marrow: 12.4,Cell line enhanced,,Daudi: 4.3;EFO-21: 3.6;HDLM-2: 4.0
192,PIK3AP1,"BCAP, FLJ35564",ENSG00000155629,Phosphoinositide-3-kinase adaptor protein 1,10,96593312-96720514,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB026136, HPA038452",Enhanced,,Approved,Nucleus<br>Plasma membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,spleen: 85.6,lymph node: 72.0,Cell line enhanced,,Daudi: 60.8;REH: 166.9;THP-1: 62.4;U-698: 79.5;U-937: 74.4
193,PITPNM3,"ACKR6, CORD5, NIR1, RDGBA3",ENSG00000091622,PITPNM family member 3,17,6451264-6556494,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA022432, HPA059005",Enhanced,,Approved,Plasma membrane,Head and neck cancer:3.67e-6 (favourable),Mixed,Tissue enhanced,,spleen: 76.8,ovary: 33.7,Cell line enhanced,,HaCaT: 15.7;hTCEpi: 36.7
194,PKD2L1,"PCL, PKD2L, PKDL, TRPP3",ENSG00000107593,"Polycystin 2 like 1, transient receptor potential cation channel",10,100288154-100330486,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,CAB022621,Uncertain,,,,,Mixed,Tissue enhanced,,spleen: 9.8,lung: 3.4,Not detected,,
195,PLCB2,FLJ38135,ENSG00000137841,Phospholipase C beta 2,15,40278176-40307935,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009443, HPA041298",Approved,,Approved,Cytosol,"Renal cancer:7.20e-5 (unfavourable), Head and neck cancer:3.00e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 55.9,appendix: 38.2,Cell line enhanced,,HEL: 70.2;HMC-1: 82.2;U-937: 41.8
196,PLEKHG1,"ARHGEF41, KIAA1209",ENSG00000120278,Pleckstrin homology and RhoGEF domain containing G1,6,150599883-150843665,Predicted intracellular proteins,Evidence at protein level,"HPA027128, HPA027319, HPA028270",Approved,,Enhanced,Nucleoplasm,,Expressed in all,Tissue enhanced,,spleen: 48.4,lymph node: 23.1,Cell line enhanced,,AF22: 18.8;HAP1: 29.5;Karpas-707: 16.8
197,PRF1,"HPLH2, P1, PFP",ENSG00000180644,Perforin 1,10,70597348-70602775,"Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB002436, HPA037940",Approved,,Approved,Cytosol,"Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:2.09e-4 (favourable), Head and neck cancer:3.54e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 52.8,lymph node: 20.8,Cell line enriched,16.0,HDLM-2: 221.2
198,PRR5L,"FLJ14213, PROTOR-2",ENSG00000135362,Proline rich 5 like,11,36296288-36465204,Predicted intracellular proteins,Evidence at protein level,HPA070174,,,Approved,Cytokinetic bridge<br>Cytosol,"Renal cancer:7.71e-8 (unfavourable), Endometrial cancer:7.30e-5 (favourable), Stomach cancer:4.86e-4 (unfavourable)",Expressed in all,Tissue enhanced,,spleen: 51.1,colon: 35.0,Cell line enhanced,,HMC-1: 51.8;hTERT-HME1: 46.7;SiHa: 43.9
199,PSTPIP2,,ENSG00000152229,Proline-serine-threonine phosphatase interacting protein 2,18,45983536-46072272,Predicted intracellular proteins,Evidence at protein level,"HPA040923, HPA040944",Enhanced,,Approved,Nucleus<br>Plasma membrane<br>Mitochondria,Renal cancer:2.39e-7 (unfavourable),Expressed in all,Tissue enhanced,,bone marrow: 47.2;spleen: 69.7,placenta: 17.3,Cell line enhanced,,HEL: 91.3;HMC-1: 95.2
200,PTCRA,"PT-ALPHA, PTA",ENSG00000171611,Pre T-cell antigen receptor alpha,6,42915989-42925835,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,lymph node: 3.2;spleen: 4.8,lung: 2.1,Group enriched,12.0,MOLT-4: 33.3;SK-MEL-30: 10.7
201,PTGDR,"DP, DP1, PTGDR1",ENSG00000168229,Prostaglandin D2 receptor,14,52267713-52276724,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,rectum: 8.6;spleen: 8.7,colon: 5.6,Not detected,,
202,PTGER1,EP1,ENSG00000160951,Prostaglandin E receptor 1,19,14472466-14475362,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,kidney: 2.9;spleen: 2.5,lung: 0.7,Cell line enhanced,,HEL: 2.2;PC-3: 2.9;SH-SY5Y: 1.9
203,PTPRCAP,"CD45-AP, LPAP",ENSG00000213402,"Protein tyrosine phosphatase, receptor type C associated protein",11,67435510-67438067,Predicted secreted proteins,Evidence at protein level,HPA043734,Enhanced,,,,,Not detected,Tissue enhanced,,appendix: 64.0;lymph node: 91.4;spleen: 84.9,tonsil: 29.0,Cell line enhanced,,Daudi: 161.8;HDLM-2: 148.3;MOLT-4: 110.0;NB-4: 409.0;U-698: 109.1
204,PVRIG,"C7orf15, MGC2463",ENSG00000213413,Poliovirus receptor related immunoglobulin domain containing,7,100218241-100221490,Predicted membrane proteins,Evidence at protein level,HPA047497,Uncertain,,Approved,Nucleoli<br>Endoplasmic reticulum,,Not detected,Tissue enhanced,,lymph node: 20.5;spleen: 11.0,appendix: 8.4,Group enriched,23.0,Daudi: 69.1;MOLT-4: 86.0;U-698: 21.4
205,PYHIN1,"IFIX, MGC23885",ENSG00000163564,Pyrin and HIN domain family member 1,1,158930796-158977054,Predicted intracellular proteins,Evidence at protein level,HPA051224,Enhanced,,,,,Mixed,Tissue enhanced,,lymph node: 26.3;spleen: 19.2,tonsil: 11.3,Cell line enriched,6.0,U-698: 33.8
206,RASGRP2,CALDAG-GEFI,ENSG00000068831,RAS guanyl releasing protein 2,11,64726911-64745456,"Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA015667,Approved,,,,Renal cancer:1.38e-4 (unfavourable),Mixed,Tissue enhanced,,lymph node: 122.0;spleen: 107.0,bone marrow: 94.3,Cell line enhanced,,HEL: 90.3;HL-60: 145.9;NB-4: 219.4;REH: 94.2;THP-1: 72.4
207,RENBP,"RBP, RNBP",ENSG00000102032,Renin binding protein,X,153935263-153944691,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000428, HPA000522",Enhanced,,,,"Renal cancer:3.08e-5 (favourable), Cervical cancer:3.95e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 58.5,kidney: 37.8,Cell line enhanced,,EFO-21: 31.9;HMC-1: 101.6;SK-MEL-30: 61.5;U-266/84: 49.9
208,RGS18,RGS13,ENSG00000150681,Regulator of G-protein signaling 18,1,192158457-192185815,Predicted intracellular proteins,Evidence at protein level,"HPA028727, HPA045780",Uncertain,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,spleen: 35.0,appendix: 19.2,Group enriched,6.0,HEL: 53.8;HL-60: 36.8;NB-4: 27.4;U-937: 31.1
209,RGS19,"GAIP, RGSGAIP",ENSG00000171700,Regulator of G-protein signaling 19,20,64073181-64079988,Predicted intracellular proteins,Evidence at protein level,"HPA056384, HPA069984",Enhanced,,Supported,Nucleoli fibrillar center<br>Cell Junctions,"Renal cancer:2.06e-9 (unfavourable), Liver cancer:2.75e-4 (unfavourable)",Expressed in all,Tissue enhanced,,spleen: 53.7,lymph node: 39.8,Expressed in all,,
210,ROBO4,"ECSM4, FLJ20798, MRB",ENSG00000154133,Roundabout guidance receptor 4,11,124883691-124898500,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA065212,,,Approved,Plasma membrane,"Liver cancer:4.85e-4 (favourable), Stomach cancer:8.73e-4 (unfavourable)",Expressed in all,Tissue enhanced,,spleen: 58.2,adipose tissue: 45.1,Group enriched,9.0,HUVEC TERT2: 203.4;TIME: 180.3
211,RP11-599B13.6,,ENSG00000263620,,17,8150816-8162975,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,colon: 5.2;spleen: 5.1;stomach: 4.5,adipose tissue: 3.8,Cell line enhanced,,HDLM-2: 28.8;HEK93: 11.5;REH: 14.0
212,RUFY4,"FLJ46536, ZFYVE31",ENSG00000188282,RUN and FYVE domain containing 4,2,218034960-218090581,Predicted intracellular proteins,Evidence at protein level,HPA037980,Uncertain,,,,,Mixed,Tissue enhanced,,spleen: 2.5,lymph node: 1.3,Cell line enriched,12.0,Karpas-707: 7.6
213,RUNX3,"AML2, CBFA3, PEBP2A3",ENSG00000020633,Runt related transcription factor 3,1,24899511-24965121,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA004195, CAB025416, HPA059006",Enhanced,,Supported,Nucleus<br>Cytosol,"Renal cancer:5.59e-5 (unfavourable), Colorectal cancer:8.71e-4 (unfavourable)",Expressed in all,Tissue enhanced,,spleen: 50.5,bone marrow: 45.2,Cell line enhanced,,HDLM-2: 125.1;Karpas-707: 125.3;SK-MEL-30: 77.0
214,S1PR4,EDG6,ENSG00000125910,Sphingosine-1-phosphate receptor 4,19,3172346-3180332,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA060601, HPA067232",,,Uncertain,Mitochondria,"Head and neck cancer:1.45e-6 (favourable), Cervical cancer:1.33e-4 (favourable), Endometrial cancer:2.22e-4 (favourable), Renal cancer:2.87e-4 (unfavourable), Breast cancer:3.13e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 18.1;spleen: 26.4,appendix: 14.0,Cell line enhanced,,HDLM-2: 22.2;HL-60: 25.5;NB-4: 19.9;REH: 81.1;U-937: 23.6
215,SAMD3,"bA73O6.2, FLJ34032",ENSG00000164483,Sterile alpha motif domain containing 3,6,130144315-130365425,Predicted intracellular proteins,Evidence at protein level,"HPA028992, HPA028993",Uncertain,,,,,Not detected,Tissue enhanced,,spleen: 13.0,lymph node: 11.5,Group enriched,5.0,HBF TERT88: 1.7;HDLM-2: 3.1;hTEC/SVTERT24-B: 2.2;NTERA-2: 1.7;PC-3: 1.1
216,SAP25,FLJ00248,ENSG00000205307,Sin3A associated protein 25,7,100572228-100573820,Predicted intracellular proteins,Evidence at protein level,HPA062610,Uncertain,,Approved,Nuclear bodies,,Mixed,Tissue enhanced,,spleen: 48.2,lymph node: 32.7,Cell line enhanced,,HMC-1: 26.8;NB-4: 44.5;U-937: 21.3
217,SASH3,"753P9, CXorf9, HACS2, SH3D6C, SLY",ENSG00000122122,SAM and SH3 domain containing 3,X,129779979-129795201,Predicted intracellular proteins,Evidence at protein level,HPA001085,Enhanced,,Approved,Plasma membrane,"Renal cancer:6.51e-5 (unfavourable), Endometrial cancer:3.15e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 136.7;spleen: 99.3;tonsil: 97.4,appendix: 80.4,Cell line enhanced,,Daudi: 116.3;MOLT-4: 95.0;NB-4: 56.4;REH: 79.9;U-698: 101.7;U-937: 90.0
218,SCARF1,"KIAA0149, SREC",ENSG00000074660,Scavenger receptor class F member 1,17,1633858-1645747,Predicted secreted proteins,Evidence at protein level,HPA072936,Enhanced,,,,,Expressed in all,Tissue enhanced,,spleen: 16.6,lung: 8.0,Cell line enhanced,,HEL: 5.0;HUVEC TERT2: 15.4;REH: 8.9;TIME: 19.1
219,SCIMP,"C17orf87, DTFT5783, FLJ32580, MGC163426, MGC163428, UNQ5783",ENSG00000161929,SLP adaptor and CSK interacting membrane protein,17,5208961-5234860,Predicted membrane proteins,Evidence at protein level,HPA006117,Enhanced,,,,,Mixed,Tissue enhanced,,spleen: 68.5,lymph node: 45.9,Cell line enhanced,,U-698: 7.7
220,SCN11A,"NaN, Nav1.9, SCN12A, SNS-2",ENSG00000168356,Sodium voltage-gated channel alpha subunit 11,3,38845769-38950561,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA036746, HPA036747",Uncertain,,,,,Not detected,Tissue enhanced,,placenta: 3.7;spleen: 5.3,testis: 2.0,Cell line enhanced,,HDLM-2: 1.1
221,SELL,"CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR",ENSG00000188404,Selectin L,1,169690667-169711698,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB002144, HPA051972",Enhanced,,Approved,Cytosol,"Renal cancer:4.96e-5 (unfavourable), Cervical cancer:2.25e-4 (favourable), Ovarian cancer:3.14e-4 (favourable), Breast cancer:3.76e-4 (favourable), Head and neck cancer:6.43e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 254.9;spleen: 219.3;tonsil: 179.1,appendix: 152.7,Cell line enhanced,,EFO-21: 9.7;MOLT-4: 16.7;U-266/70: 28.0;U-698: 12.2
222,SEMA7A,"CD108, H-Sema-L, SEMAL",ENSG00000138623,Semaphorin 7A (John Milton Hagen blood group),15,74409289-74434467,"Blood group antigen proteins, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008210, HPA042273",Uncertain,,Uncertain,Vesicles,Renal cancer:2.45e-11 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 59.6;testis: 56.9,placenta: 44.8,Cell line enhanced,,HMC-1: 510.6;hTEC/SVTERT24-B: 213.0;U-251 MG: 310.7
223,SEPT1,"DIFF6, PNUTL3",ENSG00000180096,Septin 1,16,30378133-30395991,Predicted intracellular proteins,Evidence at protein level,"HPA041566, HPA060339",Enhanced,,Uncertain,Actin filaments,"Renal cancer:2.40e-7 (unfavourable), Endometrial cancer:3.04e-5 (favourable), Lung cancer:7.24e-5 (favourable), Cervical cancer:9.72e-5 (favourable), Pancreatic cancer:2.22e-4 (favourable), Head and neck cancer:6.63e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 16.3;spleen: 11.3,tonsil: 6.0,Cell line enhanced,,Daudi: 27.2;MOLT-4: 53.0;REH: 35.4;U-266/84: 23.4
224,SH2D1A,"DSHP, EBVS, IMD5, LYP, MTCP1, SAP, XLP, XLPD",ENSG00000183918,SH2 domain containing 1A,X,124227868-124373197,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:4.94e-6 (unfavourable), Breast cancer:2.03e-4 (favourable)",Mixed,Tissue enhanced,,lymph node: 36.3;spleen: 17.5,tonsil: 13.2,Group enriched,6.0,HDLM-2: 89.9;Karpas-707: 148.7;MOLT-4: 209.2
225,SH2D1B,EAT2,ENSG00000198574,SH2 domain containing 1B,1,162395266-162412138,Predicted intracellular proteins,Evidence at protein level,HPA054791,Uncertain,,,,,Not detected,Tissue enhanced,,spleen: 10.3,lung: 3.3,Cell line enhanced,,CAPAN-2: 1.3;EFO-21: 2.5;Karpas-707: 3.2;TIME: 1.1
226,SIGLEC10,"MGC126774, PRO940, SIGLEC-10, SLG2",ENSG00000142512,Sialic acid binding Ig like lectin 10,19,51410021-51417803,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB025807, HPA027093",Enhanced,,Supported,Plasma membrane<br>Actin filaments<br>Cytosol,Renal cancer:4.74e-5 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 48.4;spleen: 36.9,lymph node: 22.1,Cell line enhanced,,Daudi: 21.0;HEL: 13.5;HMC-1: 10.2;U-698: 14.8;U-937: 9.7
227,SIGLEC12,"S2V, Siglec-12, Siglec-L1, Siglec-XII, SIGLECL1, SLG",ENSG00000254521,Sialic acid binding Ig like lectin 12 (gene/pseudogene),19,51491357-51501789,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,appendix: 6.4;spleen: 12.8,smooth muscle: 3.7,Group enriched,9.0,HMC-1: 124.2;U-937: 61.4
228,SIGLEC14,,ENSG00000254415,Sialic acid binding Ig like lectin 14,19,51642553-51646801,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA014377,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 34.8;spleen: 55.2,bone marrow: 18.3,Group enriched,10.0,HMC-1: 87.0;U-937: 19.3
229,SIGLEC5,"CD170, CD33L2, OB-BP2, SIGLEC-5",ENSG00000105501,Sialic acid binding Ig like lectin 5,19,51611927-51645545,"CD markers, Predicted membrane proteins",Evidence at protein level,"HPA009085, CAB024900",Supported,,,,,Tissue enhanced,Tissue enhanced,,appendix: 9.3;bone marrow: 9.7;spleen: 8.8,lymph node: 3.5,Group enriched,7.0,HMC-1: 52.0;U-937: 19.9
230,SIGLEC7,"CD328, p75/AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2",ENSG00000168995,Sialic acid binding Ig like lectin 7,19,51142299-51153526,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,spleen: 21.0,appendix: 14.4,Group enriched,10.0,Karpas-707: 39.7;RPMI-8226: 23.1;U-937: 27.4
231,SIGLEC9,CD329,ENSG00000129450,Sialic acid binding Ig like lectin 9,19,51124908-51136651,Predicted membrane proteins,Evidence at protein level,HPA010682,Uncertain,,,,Renal cancer:6.17e-5 (unfavourable),Mixed,Tissue enhanced,,appendix: 24.7;spleen: 23.5,lung: 12.2,Group enriched,7.0,Karpas-707: 16.8;RPMI-8226: 11.4
232,SIPA1,SPA1,ENSG00000213445,Signal-induced proliferation-associated 1,11,65638097-65650930,Predicted intracellular proteins,Evidence at protein level,"CAB020833, HPA039867",Enhanced,,Approved,Nucleus<br>Nucleoli<br>Golgi apparatus<br>Plasma membrane,"Renal cancer:3.52e-6 (unfavourable), Colorectal cancer:9.42e-4 (unfavourable)",Expressed in all,Tissue enhanced,,spleen: 99.7,lymph node: 71.0,Expressed in all,,
233,SLAMF6,"CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000",ENSG00000162739,SLAM family member 6,1,160485030-160523262,"CD markers, Predicted membrane proteins",Evidence at protein level,"HPA051363, HPA051903",Uncertain,,,,"Renal cancer:2.09e-6 (unfavourable), Head and neck cancer:7.34e-5 (favourable), Melanoma:1.25e-4 (favourable), Cervical cancer:2.78e-4 (favourable), Breast cancer:9.42e-4 (favourable), Endometrial cancer:9.53e-4 (favourable)",Mixed,Tissue enhanced,,lymph node: 70.8;spleen: 43.3;tonsil: 44.6,appendix: 27.2,Cell line enhanced,,Daudi: 63.2;MOLT-4: 17.4;U-698: 89.3
234,SLC9A5,NHE5,ENSG00000135740,Solute carrier family 9 member A5,16,67237683-67272190,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA041004, HPA041329",Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,spleen: 7.8,cerebral cortex: 2.5,Cell line enhanced,,U-138 MG: 5.9
235,SNTG1,"G1SYN, SYN4",ENSG00000147481,Syntrophin gamma 1,8,49909789-50794118,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA072282,Supported,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 8.6;spleen: 3.8,testis: 1.2,Not detected,,
236,SNTG2,"G2SYN, SYN5",ENSG00000172554,Syntrophin gamma 2,2,950868-1367613,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,spleen: 2.5;testis: 2.4,"adipose tissue,endometrium: 2.0",Cell line enhanced,,Daudi: 1.1;HAP1: 1.8;NTERA-2: 2.1;SCLC-21H: 2.3
237,SOWAHD,ANKRD58,ENSG00000187808,Sosondowah ankyrin repeat domain family member D,X,119758613-119760164,Predicted intracellular proteins,Evidence at protein level,HPA065955,Uncertain,,,,,Tissue enriched,Tissue enhanced,,spleen: 5.0,testis: 3.6,Cell line enhanced,,BEWO: 4.3;THP-1: 5.8;U-937: 6.0
238,SPATA13,"ARHGEF29, FLJ31208",ENSG00000182957,Spermatogenesis associated 13,13,23979805-24307074,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040185, HPA041208",Approved,,Supported,Nucleoplasm<br>Cytosol,Urothelial cancer:1.16e-4 (favourable),Expressed in all,Tissue enhanced,,spleen: 90.2,lymph node: 27.2,Cell line enhanced,,HDLM-2: 43.0
239,SPSB4,SSB-4,ENSG00000175093,SplA/ryanodine receptor domain and SOCS box containing 4,3,141051402-141148611,Predicted intracellular proteins,Evidence at protein level,HPA062793,,,Approved,Nucleoplasm<br>Golgi apparatus,Glioma:2.57e-4 (favourable),Group enriched,Tissue enhanced,,cerebral cortex: 1.3;spleen: 1.5;testis: 2.4,pancreas: 1.2,Cell line enhanced,,AF22: 12.9;NTERA-2: 3.7;RH-30: 4.3;SH-SY5Y: 3.9;U-2 OS: 3.1
240,TAC1,"NKNA, NPK, TAC2",ENSG00000006128,Tachykinin precursor 1,7,97731908-97740472,Predicted secreted proteins,Evidence at protein level,"CAB004588, HPA014429",Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 77.7;spleen: 47.0,appendix: 13.2,Cell line enriched,14.0,U-266/70: 16.5
241,TBC1D10C,"Carabin, EPI64C, FLJ00332",ENSG00000175463,TBC1 domain family member 10C,11,67403915-67410089,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA069743,Enhanced,,Approved,Nuclear bodies,"Renal cancer:4.35e-7 (unfavourable), Head and neck cancer:1.86e-5 (favourable), Breast cancer:3.83e-4 (favourable), Cervical cancer:4.20e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 45.6;spleen: 37.9,appendix: 22.0,Cell line enhanced,,MOLT-4: 34.1;NB-4: 32.0;U-937: 16.2
242,TBX21,"T-bet, TBLYM",ENSG00000073861,T-box 21,17,47733244-47746119,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB009524, CAB030043",Enhanced,,,,,Mixed,Tissue enhanced,,lymph node: 8.5;spleen: 11.1,bone marrow: 6.4,Cell line enriched,152.0,HDLM-2: 15.1
243,TCF21,"bHLHa23, POD1",ENSG00000118526,Transcription factor 21,6,133889138-133895553,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA013189,Uncertain,,,,,Mixed,Tissue enhanced,,placenta: 62.4;spleen: 46.9,ovary: 32.1,Cell line enriched,10.0,HHSteC: 13.5
244,TCHH,THH,ENSG00000159450,Trichohyalin,1,152106317-152115454,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA028375,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,placenta: 1.6;spleen: 2.1,testis: 1.2,Cell line enhanced,,HaCaT: 3.2;SCLC-21H: 1.3;THP-1: 1.3
245,TDGF1,"CR, CRIPTO, Cripto-1",ENSG00000241186,Teratocarcinoma-derived growth factor 1,3,46574534-46582463,Predicted intracellular proteins,Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,spleen: 24.8,kidney: 8.1,Group enriched,30.0,HEL: 19.6;NTERA-2: 95.4
246,TLR8,CD288,ENSG00000101916,Toll like receptor 8,X,12906620-12923169,"CD markers, Predicted membrane proteins",Evidence at protein level,HPA001608,Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 23.2;lung: 15.6;spleen: 18.3,lymph node: 6.6,Not detected,,
247,TMC8,"EVER2, EVIN2",ENSG00000167895,Transmembrane channel like 8,17,78130770-78142968,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA047387, HPA054429",Uncertain,,Uncertain,Golgi apparatus,"Renal cancer:1.96e-7 (unfavourable), Cervical cancer:8.45e-6 (favourable), Head and neck cancer:4.19e-5 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 118.8;spleen: 104.5,appendix: 72.5,Cell line enhanced,,HL-60: 50.1;HMC-1: 106.6;Karpas-707: 74.8;RPMI-8226: 46.3;U-266/70: 38.2;U-937: 41.2
248,TMEM26,"Em:AC068892.1, MGC35010",ENSG00000196932,Transmembrane protein 26,10,61406643-61453450,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,spleen: 11.8,endometrium: 6.8,Cell line enhanced,,BJ hTERT+: 3.7;HSkMC: 1.4;HUVEC TERT2: 1.2;MOLT-4: 1.8
249,TMPRSS9,,ENSG00000178297,"Transmembrane protease, serine 9",19,2389771-2426239,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA051483,Uncertain,,,,,Mixed,Tissue enhanced,,spleen: 2.3;testis: 1.7,skin: 0.8,Cell line enhanced,,Karpas-707: 1.8;U-266/70: 1.7
250,TMTC1,"ARG99, FLJ31400, FLJ41625, OLF",ENSG00000133687,Transmembrane and tetratricopeptide repeat containing 1,12,29500840-29784759,Predicted membrane proteins,Evidence at protein level,HPA016720,Approved,,Approved,Nucleoplasm<br>Cytosol,"Endometrial cancer:1.90e-4 (unfavourable), Renal cancer:5.49e-4 (unfavourable)",Mixed,Tissue enhanced,,spleen: 60.8,adipose tissue: 41.7,Cell line enhanced,,HHSteC: 71.4;hTERT-HME1: 81.2;RH-30: 120.9
251,TNFAIP8L2,FLJ23467,ENSG00000163154,TNF alpha induced protein 8 like 2,1,151156629-151159749,Predicted intracellular proteins,Evidence at protein level,HPA062742,,,Uncertain,Vesicles,"Renal cancer:3.53e-7 (unfavourable), Melanoma:3.64e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 34.7;spleen: 39.1,appendix: 25.8,Group enriched,6.0,HEL: 26.1;HL-60: 13.6;HMC-1: 38.0;NB-4: 15.6;THP-1: 62.9;U-937: 28.8
252,TNFRSF13B,"CD267, IGAD2, TACI",ENSG00000240505,TNF receptor superfamily member 13B,17,16929816-16972118,"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030453,Uncertain,,,,,Not detected,Tissue enhanced,,lymph node: 20.3;skeletal muscle: 22.1;spleen: 27.2;tonsil: 21.0,appendix: 12.1,Group enriched,8.0,Karpas-707: 120.9;RPMI-8226: 76.1;U-266/70: 56.5
253,TRAF3IP3,T3JAM,ENSG00000009790,TRAF3 interacting protein 3,1,209756032-209782320,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040796,Enhanced,,Approved,Vesicles,"Breast cancer:4.11e-4 (favourable), Lung cancer:8.15e-4 (favourable)",Mixed,Tissue enhanced,,lymph node: 114.8;spleen: 82.5;tonsil: 82.8,appendix: 67.8,Cell line enhanced,,HDLM-2: 106.9;Karpas-707: 33.1;MOLT-4: 48.2;NB-4: 43.3;THP-1: 43.1;U-266/70: 51.7
254,TTC24,,ENSG00000187862,Tetratricopeptide repeat domain 24,1,156579727-156586770,Predicted intracellular proteins,Evidence at protein level,HPA029799,,,Approved,Nucleoplasm,,Not detected,Tissue enhanced,,lymph node: 6.4;spleen: 3.8;tonsil: 4.2,appendix: 2.4,Cell line enhanced,,MOLT-4: 2.5;REH: 10.7;U-698: 1.5
255,UBASH3B,"KIAA1959, STS-1, TULA2",ENSG00000154127,Ubiquitin associated and SH3 domain containing B,11,122655675-122814473,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038605, HPA038607",Approved,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,placenta: 19.6;spleen: 21.3,lung: 6.7,Cell line enhanced,,HEL: 108.5;HMC-1: 77.6
256,VNN2,"FOAP-4, GPI-80",ENSG00000112303,Vanin 2,6,132743870-132763459,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:2.72e-7 (unfavourable),Mixed,Tissue enhanced,,spleen: 76.9,lymph node: 45.0,Cell line enriched,6.0,Daudi: 40.8
257,WAS,"IMD2, THC, WASP, WASPA",ENSG00000015285,Wiskott-Aldrich syndrome,X,48676596-48691427,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA002022, CAB004290",Enhanced,,,,"Renal cancer:5.58e-6 (unfavourable), Head and neck cancer:3.78e-4 (favourable), Endometrial cancer:4.95e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 69.0;lymph node: 60.8;spleen: 68.8,bone marrow: 37.5,Cell line enhanced,,HMC-1: 135.1;U-937: 66.6
258,WDFY4,"C10orf64, Em:AC060234.3, FLJ45748, KIAA1607",ENSG00000128815,WDFY family member 4,10,48684876-48982956,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040634,Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,lymph node: 33.0;spleen: 23.8,tonsil: 22.1,Cell line enhanced,,Daudi: 43.5;HDLM-2: 52.1;HL-60: 17.1;U-698: 17.8;U-937: 19.6
259,WDR86,,ENSG00000187260,WD repeat domain 86,7,151375909-151410727,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 20.9;spleen: 14.3,endometrium: 7.5,Group enriched,5.0,HSkMC: 9.9;NTERA-2: 2.6;SCLC-21H: 6.9;SH-SY5Y: 4.4
260,WSCD1,KIAA0523,ENSG00000179314,WSC domain containing 1,17,5772234-6124427,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA015919,Uncertain,,Approved,Nucleoplasm<br>Golgi apparatus,,Group enriched,Tissue enhanced,,cerebral cortex: 30.3;spleen: 19.0,testis: 14.9,Cell line enhanced,,AF22: 39.4;HUVEC TERT2: 20.9;PC-3: 23.1;RH-30: 61.0;SCLC-21H: 18.5
261,XCL1,"ATAC, LPTN, LTN, SCM-1, SCM-1a, SCYC1",ENSG00000143184,X-C motif chemokine ligand 1,1,168576473-168582077,Predicted secreted proteins,Evidence at protein level,HPA057725,Approved,,,,,Mixed,Tissue enhanced,,spleen: 5.7,endometrium: 3.3,Cell line enhanced,,CACO-2: 2.4;Hep G2: 2.5;SCLC-21H: 4.0;U-266/70: 3.7
262,XCL2,"SCM-1b, SCYC2",ENSG00000143185,X-C motif chemokine ligand 2,1,168540765-168543997,Predicted secreted proteins,Evidence at protein level,HPA057725,Approved,,,,"Renal cancer:8.36e-9 (unfavourable), Lung cancer:3.17e-4 (favourable)",Mixed,Tissue enhanced,,spleen: 14.1,bone marrow: 8.4,Cell line enhanced,,CACO-2: 2.1
263,XXbac-BPG246D15.9,,ENSG00000250264,,6,32813767-32838822,Predicted membrane proteins,Evidence at transcript level,HPA001312,Approved,,Approved,Nuclear speckles<br>Endoplasmic reticulum,,Not detected,Tissue enhanced,,appendix: 15.5;spleen: 9.5,lymph node: 6.5,Cell line enhanced,,Daudi: 14.2;HDLM-2: 12.4;HEL: 12.9
264,ZAP70,"SRK, STD, ZAP-70",ENSG00000115085,Zeta chain of T-cell receptor associated protein kinase 70,2,97713560-97739862,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB002625, HPA003134",Enhanced,,,,"Renal cancer:3.02e-8 (unfavourable), Endometrial cancer:9.66e-8 (favourable), Head and neck cancer:3.93e-6 (favourable), Cervical cancer:6.89e-5 (favourable)",Mixed,Tissue enhanced,,appendix: 36.2;lymph node: 64.3;spleen: 37.7,tonsil: 16.2,Cell line enriched,16.0,MOLT-4: 144.9
